


COMPLETED
ORIGINAL

HE 20.4115:788/supp.1

(MF) 0499-K03
(612)

**CUMULATIVE
SUPPLEMENT 7
JAN'88-JUL'88**



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

8TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT

Handwritten initials and a date, possibly '1/1/88', in the bottom left corner.

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

1E240012

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS
8TH EDITION

CUMULATIVE SUPPLEMENT 7

JULY 1988

CONTENTS

	PAGE
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Products Requiring Revised Labeling for Full Approval	v
1.3 Applicant (Name) Changes	v
1.4 Report of Counts for the Prescription Drug Product List	vi
2.0 DRUG PRODUCT LISTS	
2.1 Prescription Drug Product List	1
2.2 OTC Drug Product List	42
2.3 List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act	43
2.4 Orphan Drug Products with Exclusive Approval	44
2.5 Drug Products Which Must Demonstrate <u>in vivo</u> Bioavailability Only if Product Fails to Achieve Adequate Dissolution	46
2.6 Biopharmaceutic Guidance Availability	47
2.7 ANDA Suitability Petitions	48
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Exclusivity Terms	55
B. Patent and Exclusivity Lists	57

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS
8th EDITION
CUMULATIVE SUPPLEMENT 7
JULY 1988

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 8th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products in the Division of Blood and Blood Products approved under Section 505 of the Act, and products discontinued from marketing or products which have had their approval withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product, along with the application number and product number (FDA's internal file number). All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.] The effective date for the approved drug product (the earliest date a product may be marketed) appears, when appropriate, to the left of the approval date.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (⬠) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print will remain in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data will be dropped in subsequent Cumulative Supplements.

Products discontinued from marketing or products which have had their approval withdrawn for other than safety or effectiveness reasons, will be flagged in this Cumulative Supplement with the "Ⓢ" symbol to designate their non-marketed status. All products having a "Ⓢ" symbol in the 12th Cumulative Supplement of the 8th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 9th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

<u>Products</u>	<u>Federal Register Reference</u>
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranlylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.3 APPLICANT (NAME) CHANGES

Because it is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1987) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product, provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

COUNTS CUMULATIVE BY QUARTER¹

<u>CATEGORIES COUNTED</u>	<u>DEC 1987</u>	<u>MAR 1988</u>	<u>JUN 1988</u>
DRUG PRODUCTS LISTED	9709	9528	9769*
SINGLE SOURCE	2096 (21.6%)	1997 (21.0%)	1975 (20.2%)
MULTISOURCE	7613 (78.4%)	7531 (79.0%)	7794 (79.8%)
THERAPEUTICALLY EQUIVALENT	6691 (68.9%)	6660 (69.9%)	6937 (71.0%)
NOT THERAPEUTICALLY EQUIVALENT	848 (8.7%)	770 (8.1%)	757 (7.8%)
EXCEPTIONS ²	74 (0.8%)	101 (1.0)	100 (1.0%)
NEW MOLECULAR ENTITIES APPROVED	--	1	2
NUMBER OF APPLICANTS	349	361	378

*This number is inclusive of products discontinued since December 1987, and any products approved or discontinued through July 1988.

(1) Cumulative counts are calculated from January 1, 1988 to, and including, the month indicated.

(2) Amino acid-containing products of varying composition (see Introduction, page 1-8 of the List).

PRESCRIPTION DRUG PRODUCT LIST
8TH EDITION
CUMULATIVE SUPPLEMENT NUMBER 7 / JAN '88 - JUL '88

BEST COPY AVAILABLE

1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
MIKART 500MG;50MG;40MG

N89451 001
MAY 23, 1988

BUTALBITAL, APAP, AND CAFFEINE

AB HALSEY DRUG 325MG;50MG;40MG

N89536 001
FEB 16, 1988

ACETAMINOPHEN; CODEINE PHOSPHATE

ELIXIR; ORAL

MYAPAP AND CODEINE

AA MY K LABS 120MG/5ML;12MG/5ML

N87006 001

/AA/ MYAPAP W/ CODEINE

/AA/ MY K LABS 120MG/5ML;12MG/5ML

/N87006/001/

/AA/ TYLENOL W/ CODEINE

/AA/ MCNEIL LABS 120MG/5ML;12MG/5ML

/N85057/001/

AA MCNEIL PHARM 120MG/5ML;12MG/5ML

N85057 001

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

/AA/ BOOTS LABS 300MG;60MG

/N87762/001/
DEC 10, 1982

> ADD >

ACETAMINOPHEN AND CODEINE PHOSPHATE

> ADD > AA HALSEY DRUG 300MG;60MG

N86549 001

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA MUTUAL PHARM 300MG;15MG

N89671 001

AA 300MG;30MG

FEB 10, 1988

AA 300MG;60MG

FEB 10, 1988

AA 300MG;60MG

FEB 10, 1988

AA 300MG;60MG

FEB 10, 1988

AA PHARMAFAIR 300MG;30MG

N87762 001

DEC 10, 1982

> DLT >

ACETAMINOPHEN W/ CODEINE PHOSPHATE

> DLT > /AA/ HALSEY DRUG 300MG;60MG

/N86549/001/

TYLENOL W/ CODEINE

/AA/ MCNEIL LABS 325MG;7.5MG

/N85056/001/

/AA/ 325MG;15MG

/N85056/002/

/AA/ 325MG;30MG

/N85056/003/

/AA/ 325MG;60MG

/N85056/004/

AA MCNEIL PHARM 325MG;7.5MG

N85056 001

AA 325MG;15MG

N85056 002

AA 325MG;30MG

N85056 003

AA 325MG;60MG

N85056 004

TYLENOL W/ CODEINE NO. 1

/AA/ MCNEIL LABS 300MG;7.5MG

/N85055/001/

AA MCNEIL PHARM 300MG;7.5MG

N85055 001

TYLENOL W/ CODEINE NO. 2

/AA/ MCNEIL LABS 300MG;15MG

/N85055/002/

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

TYLENOL W/ CODEINE NO. 2

AA MCNEIL PHARM 300MG;15MG

N85055 002

TYLENOL W/ CODEINE NO. 3

/AA/ MCNEIL LABS 300MG;30MG

/N85055/003/

AA MCNEIL PHARM 300MG;30MG

N85055 003

TYLENOL W/ CODEINE NO. 4

/AA/ MCNEIL LABS 300MG;60MG

/N85055/004/

AA MCNEIL PHARM 300MG;60MG

N85055 004

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

CO-GESTIC

AA CENTRAL PHARMS 500MG;5MG

N89360 001
MAR 02, 1988

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA BEECHAM LABS 650MG;7.5MG

N89725 001
SEP 30, 1987

AA LUCHEM PHARMS 500MG;5MG

N89696 001

AA MIKART 650MG;7.5MG

APR 21, 1988

AA 650MG;7.5MG

N89689 001

JUN 29, 1988

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB HALSEY DRUG 325MG;50MG

N72105 001
MAY 13, 1988

AB 650MG;100MG

N72106 001

AB 650MG;100MG

MAY 13, 1988

AB 650MG;100MG

N72195 001

FEB 16, 1988

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

AB MUTUAL PHARM 125MG

N89752 001
JUN 22, 1988

AB 250MG

N89753 001

AB 125MG

JUN 22, 1988

DIAMOX

AB LEDERLE LABS 125MG

N80943 001

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM
 AP QUAD PHARMS 500MG/VIALM N89619 001
 JAN 13, 1988
 DIANON
 AP LEDERLE LABS 500MG/VIAL N09388 001

ALBUTEROL SULFATE

CAPSULE; INHALATION
 VENTOLIN ROTACAPS
 GLAXO EQ 0.2MG BASEM N19489 001
 MAY 04, 1988

ALSEROXYLON

TABLET; ORAL
 RAUTENSIN
 /BP/ /DORSEY/LABS/ /2MG/ N09215/001/
 3 DORSEY LABS 2MG N09215 001

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
 /AMANTADINE HCL/
 > DLT > /44/ /REID/ROWELL/ /100MG/ N71000/001/
 > DLT > /SEP/04/1986/
 > DLT >
 > ADD >
 > ADD > AB SYMADINE 100MG N71000 001
 > ADD > REID ROWELL SEP 04, 1986

AMCINONIDE

LOTION; TOPICAL
 CYCLOCORT
 LEDERLE LABS 0.1% N19729 001
 JUN 13, 1988

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE
 AB BARR LABS 5MG;50MG N71111 001
 MAY 10, 1988

AMINO ACIDS

INJECTABLE; INJECTION
 NEOPHAM 6.4%
 /KABIVITRUM/ /6.4%/
 3 KABIVITRUM 6.4% N18792/001/
 /JAN/17/1984/
 N18792 001
 JAN 17, 1984
 TRAVASOL 10% IN PLASTIC CONTAINER
 BAXTER 10% N18931 004
 APR 27, 1988

> ADD > AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM
 > ADD > ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
 > ADD >
 > ADD > INJECTABLE; INJECTION
 > ADD > FREAMINE III 8.5% W/ ELECTROLYTES
 > ADD > KENDALL MCGAW 8.5%;110MG/100ML;230MG/100ML;
 > ADD > 10MG/100ML;440MG/100ML;
 > ADD > 690MG/100ML N16822 007
 > ADD > JUL 01, 1988

AMINOCAPROIC ACID

INJECTABLE; INJECTION
AMINOCAPROIC ACID
 AP ABBOTT LABS 250MG/MLM N70888 001
 JUN 16, 1988

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION
AMINOHIPPURATE SODIUM
 > ADD > AP MS&D 20% N05619 001
 > ADD > AP QUAD PHARMS 20% N89821 001
 > ADD > JUL 14, 1988

AMINOPHYLLINE

TABLET; ORAL
 AMINOPHYLLINE
 /BP/ /BARR/LABS/ /100MG/ N88297/001/
 /AUG/19/1983/
 /BP/ /200MG/ N88298/001/
 /AUG/19/1983/
 3 BARR LABS 100MG N88297 001
 AUG 19, 1983
 3 200MG N88298 001
 AUG 19, 1983

BEST COPY AVAILABLE

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / JAN'88 - JUL'88

3


AMINOPHYLLINE

TABLET; ORAL		
AMINOPHYLLINE		
/B0//13/VALE/CHEM/	/100MG/	/N84533/001/
VALE CHEM	100MG	N84533 001

AMINOSALICYLATE SODIUM

TABLET; ORAL		
TEEBACIN		
/B0//13/CNSOL/MIDLAND/	/500MG/	/N07320/002/
3 CNSOL MIDLAND	500MG	N07320 002

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL		
AMITRIPTIL		
/AB//	/10MG/	
/AB//	/25MG/	
/AB//	/50MG/	
/AB//	/75MG/	
/AB//	/100MG/	
/AB//	/150MG/	
AB	10MG	N83937 001
AB	25MG	N83938 002
AB	50MG	N84957 001
AB	75MG	N85093 001
AB	100MG	N86295 001
AB	150MG	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL		
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL		
AB	PAR PHARM	EQ 12.5MG BASE; 5MG
		N72277 001
		MAY 09, 1988
AB		25MG; 10MG
		N72278 001
		MAY 09, 1988
AB	PHARM BASICS	EQ 12.5MG BASE; 5MG
		N70477 001
		JAN 12, 1988
AB		EQ 25MG BASE; 10MG
		N70478 001
		JAN 12, 1988

AMOXICILLIN

CAPSULE; ORAL		
AMOXICILLIN		
AB	CLONMEL CHEMS	250MG
		N62884 001
		FEB 25, 1988
AB		500MG
		N62881 001
		FEB 25, 1988

POWDER FOR RECONSTITUTION; ORAL

POLYMOX		
AB	BRSTL MYRS IND	125MG/5ML
		N62885 001
		MAR 08, 1988
AB		250MG/5ML
		N62885 002
		MAR 08, 1988

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL		
AMPICILLIN		
AB	CLONMEL CHEMS	EQ 250MG BASE
		N62883 001
		FEB 25, 1988
AB		EQ 500MG BASE
		N62882 001
		FEB 25, 1988
POLYCYLLIN		
AB	BRSTL MYRS IND	EQ 250MG BASE
		N62888 001
		MAR 04, 1988
AB		EQ 500MG BASE
		N62888 002
		MAR 04, 1988

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL		
ORPHENADRINE COMPOUND		
AB	VITARINE	385MG; 30MG; 25MG
		N71564 001
		JUN 23, 1988
ORPHENADRINE COMPOUND DOUBLE STRENGTH		
AB	VITARINE	770MG; 60MG; 50MG
		N71565 001
		JUN 23, 1988

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL		
COMPOUND 65		
/AB//	/BANMAX/PHARMS/	/389MG; 32.4MG; 65MG/
		/N84553/002/
		/AUG/17/1988/
	3 BANMAX PHARMS	389MG; 32.4MG; 65MG
		N84553 002
		AUG 17, 1988

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

CENTRAL PHARMS

500MG;5MG

N89420 001
JAN 25, 1988ATENOLOL

TABLET; ORAL

ATENOLOL

ICI PHARMS

50MG

N72303 001
JUL 15, 1988

> ADD >

> ADD > AB

> ADD >

> ADD > AB

> ADD >

TENORMIN

STUART PHARMS

50MG

N18240 001
N18240 002

> ADD > AB

> ADD > AB

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

ATROPINE

/S/CARNRICK LABS/

/0.025MG;1MG/
0.025MG;1MG/N17744/002/
N17744 002

> DLT >

> DLT >

> ADD >

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE

AP QUAD PHARMS

EQ 100MG BASE/VIAL

N71056 001
JUN 08, 1988IMURAN

AP BURROUGHS WELLC

EQ 100MG BASE/VIAL

N17391 001

BACLOFEN

TABLET; ORAL

BACLOFEN

AB PHARM BASICS

10MG

N71260 001
MAY 06, 1988

AB

20MG

N71261 001
MAY 06, 1988

AB

VITARINE

10MG

N71901 001
APR 13, 1988

AB

20MG

N71902 001
APR 13, 1988BACLOFEN

TABLET; ORAL

BACLOFEN

ZENITH LABS

10MG

N72234 001

> ADD > AB

> ADD >

> ADD > AB

> ADD >

20MG

JUL 21, 1988

N72235 001

JUL 21, 1988

LTORISAL

AB

GEIGY PHARMS

10MG

N17851 001

LTORISAL DS

AB

GEIGY PHARMS

20MG

N17851 003

JAN 20, 1982

BENZTHIAZIDE

TABLET; ORAL

BENZTHIAZIDE/BP/ /PRIVATE/FMLTNS/
3 PRIVATE FMLTNS/50MG/
50MG/N83206/001/
N83206 001BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA

PAR PHARM

0.5MG

N88877 001

APR 11, 1985

AA

1MG

N88894 001

APR 11, 1985

AA

2MG

N88895 001

APR 11, 1985

/BP/

/0.5MG/

/N88877/001/

/APR 11, 1985/

/BP/

/1MG/

/N88894/001/

/APR 11, 1985/

/BP/

/2MG/

/N88895/001/

/APR 11, 1985/

AA

PHARM BASICS

0.5MG

N89211 001

JUN 14, 1988

AA

1MG

N89212 001

JUN 14, 1988

AA

2MG

N89213 001

JUN 14, 1988

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA QUANTUM PHARMS 0.5MG

N88514 001

JAN 31, 1984

AA 1MG

N88510 001

JAN 31, 1984

AA 2MG

N88511 001

/BP/ /0.5MG/

/BP/ /1MG/

/BP/ /2MG/

COSENTIN

AA MS&D 0.5MG

N09193 004

AA 1MG

N09193 003

AA 2MG

N09193 002

/BP/ /0.5MG/

/N09193/004/

/BP/ /1MG/

/N09193/003/

/BP/ /2MG/

/N09193/002/

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB COPLEY PHARM EQ 0.05% BASEM

N71882 001

JUN 06, 1988

BETAMETHASONE VALERATE

CREAM; TOPICAL

DERMABET

AB TARO PHARMS EQ 0.1% BASEM

N72041 001

JAN 06, 1988

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB COPLEY PHARM EQ 0.1% BASEM

N71883 001

APR 22, 1988

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

> DLT > /LILLY/ /50MG/ML/

/N09344/001/

> ADD > 2 LILLY 50MG/ML

N09344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

BETHANECHOL CHLORIDE

AP QUAD PHARMS 5MG/MLM

N89815 001

APR 12, 1988

AP URECHOLINE

AP MS&D 5MG/ML

N06536 001

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

> ADD > AP LUITPOLD PHARMS 50MG/MLM

N70891 001

> ADD > AP QUAD PHARMS 50MG/MLM

JUL 26, 1988

N71181 001

FEB 16, 1988

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

/AB/ /BARR/LABS/ /4MG/

/N84468/001/

2 BARR LABS 4MG

N84468 001

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE

ABBOTT LABS 0.25%;0.005MG/MLM

N71166 001

JUN 16, 1988

0.25%;0.005MG/MLM

N71165 001

JUN 16, 1988

0.25%;0.005MG/MLM

N71167 001

JUN 16, 1988

0.5%;0.005MG/MLM

N71168 001

JUN 16, 1988

0.5%;0.005MG/MLM

N71169 001

JUN 16, 1988

0.5%;0.005MG/MLM

N71170 001

JUN 16, 1988

0.75%;0.005MG/MLM

N71171 001

JUN 16, 1988

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATESOLUTION; INTRAPERITONEAL

<u>DIANEAL PD-1 M/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>			
AT	BAXTER	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100MLM	N17512 010 NOV 18, 1985
<u>DIANEAL PD-2 M/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>			
AT	BAXTER	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100MLM	N17512 011 NOV 18, 1985
<u>INPER3OL M/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>			
AT	ABBOTT LABS	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100MLM	N18379 007 JUN 24, 1988
<u>INPER3OL-LM M/ DEXTROSE 3.5% IN PLASTIC CONTAINER</u>			
AT	ABBOTT LABS	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100MLM	N18379 008 JUN 24, 1988

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATEINJECTABLE; INJECTION

<u>DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER</u>			
	KENDALL MCGAN	10MG/100ML; 2.5GM/100ML; 15MG/100ML; 300MG/100ML; 160MG/100MLM	N19634 001 FEB 24, 1988
<u>DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER</u>			
	KENDALL MCGAN	4MG/100ML; 4GM/100ML; 6MG/100ML; 120MG/100ML; 62MG/100MLM	N19634 002 FEB 24, 1988
<u>DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER</u>			
AP	KENDALL MCGAN	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100MLM	N19634 003 FEB 24, 1988

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATEINJECTABLE; INJECTION

<u>LACTATED RINGER'S IN PLASTIC CONTAINER</u>			
AP	KENDALL MCGAN	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100MLM	N19632 001 FEB 29, 1988

CARBAMAZEPINETABLET, CHEWABLE; ORAL

<u>CARBAMAZEPINE</u>			
AB	WARNER CHILCOTT	100MG	N71940 001 FEB 01, 1988
<u>TEGRETOL</u>			
AB	GEIGY PHARMS	100MG	N18281 001

CEFACTORPOWDER FOR RECONSTITUTION; ORAL

CECLOR		
LILLY	EQ 187MG BASE/5MLM	N62206 003 APR 20, 1988
	EQ 375MG BASE/5MLM	N62206 004 APR 20, 1988

CEFAZOLIN SODIUMINJECTABLE; INJECTION

<u>ANCEF</u>			
AP	SK&F LABS	EQ 5GM BASE/VIAL	N50461 004
<u>CEFAZOLIN SODIUM</u>			
	BEN VENUE LABS	EQ 250MG BASE/VIALM	N62894 001 JUL 21, 1988
> ADD > AP		EQ 500MG BASE/VIALM	N62894 002 JUL 21, 1988
> ADD > AP		EQ 1GM BASE/VIALM	N62894 003 JUL 21, 1988
> ADD > AP		EQ 5GM BASE/VIALM	N62894 004 JUL 21, 1988
> ADD > AP		EQ 10GM BASE/VIALM	N62894 005 JUL 21, 1988

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	ELKINS SINN	EQ 250MG BASE/VIALM	N62807 001 JAN 12, 1988
AP		EQ 500MG BASE/VIALM	N62807 002 JAN 12, 1988
AP		EQ 1GM BASE/VIALM	N62807 003 JAN 12, 1988
AP		EQ 5GM BASE/VIALM	N62807 004 JAN 12, 1988
AP		EQ 10GM BASE/VIALM	N62807 005 JAN 12, 1988
AP		EQ 20GM BASE/VIALM	N62807 006 JAN 12, 1988

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

STUART PHARMS

EQ 10GM BASE/VIALM	N50588 003 APR 25, 1988
--------------------	----------------------------

CEPHALEXIN

CAPSULE; ORAL

CEPHALIDIN

> ADD >	AB	LABROS ATRAL	EQ 250MG BASEM	N62713 001 JUL 15, 1988
> ADD >			EQ 500MG BASEM	N62713 002 JUL 15, 1988
> ADD >	AB	JEROME STEVENS	EQ 250MG BASEM	N62870 001 MAR 17, 1988
> ADD >			EQ 500MG BASEM	N62869 001 MAR 17, 1988
	AB	TAG PHARMS	EQ 250MG BASEM	N62821 001 FEB 05, 1988
			EQ 500MG BASEM	N62823 001 FEB 05, 1988
	AB	YOSHITOMI PHARM	EQ 250MG BASEM	N62872 001 JUN 20, 1988
> ADD >	AB		EQ 500MG BASEM	N62871 001 JUL 05, 1988

POWDER FOR RECONSTITUTION; ORAL

CEPHALIDIN

AB	TAG PHARMS	EQ 125MG BASE/5MLM	N62873 001 MAY 23, 1988
AB		EQ 250MG BASE/5MLM	N62867 001 APR 15, 1988

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

LILLY

EQ 333MG BASEM	N50614 003 MAY 16, 1988
----------------	----------------------------

CEPHRADINE

CAPSULE; ORAL

CEPHRADINE

AB	BARR LABS	250MGM	N62850 001 APR 22, 1988
AB		500MGM	N62851 001 APR 22, 1988
AB	VITARINE	250MGM	N62813 001 FEB 25, 1988
AB		500MGM	N62813 002 FEB 25, 1988

POWDER FOR RECONSTITUTION; ORAL

CEPHRADINE

AB	BARR LABS	125MG/5MLM	N62858 001 MAY 19, 1988
AB		250MG/5MLM	N62859 001 MAY 19, 1988

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

> ADD >	AB	PIONEER PHARMS	10MGM	N89533 001 JUL 15, 1988
> ADD >			25MGM	N89558 001 JUL 15, 1988
> ADD >	AB	PUREPAC/PHARM/	5MG/	N85155/001/
	AB		10MG/	N84939/002/
	AB		25MG/	N85144/001/
		PUREPAC PHARM	5MG	N85155 001
			10MG	N84939 002
			25MG	N85144 001
		LYGEN		
	AB	BANMAX/PHARMS/	5MG/	N85107/002/
	AB		10MG/	N85009/001/
	AB		25MG/	N85108/001/
		BANMAX PHARMS	5MG	N85107 002
			10MG	N85009 001
			25MG	N85108 001

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
 CHLOROTHIAZIDE W/ RESERPINE
 /BP/ /BOLAR/PHARM/ /250MG;0.125MG/
 2 BOLAR PHARM 250MG;0.125MG

/N84853/001/
 N84853 001

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL
 CHOLYBAR
 PARKE DAVIS

EQ 4GM RESIN/BARM
 EQ 4GM RESIN/BARM

N71621 001
 MAY 26, 1988
 N71739 001
 MAY 26, 1988

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
 CHLORPHENIRAMINE MALEATE
 /BA/ /BARR/LABS/ /4MG/
 2 BARR LABS 4MG

/N80700/001/
 N80700 001

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
 CLEOCIN
 UPJOHN MFG

EQ 75MG BASE
 EQ 150MG BASE

N61809 001
 N61809 002

> ADD > AB
 > ADD > AB

CLEOCIN HCL
 UPJOHN

EQ 300MG BASEM

N50162 003
 APR 14, 1988

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
 CHLORPROMAZINE HCL
 AP MARSAM PHARMS 25MG/MLM

N89563 001
 APR 15, 1988

> ADD >
 > ADD > AB
 > ADD >
 > ADD > AB
 > ADD >

CLINDAMYCIN HCL
 VITARINE

EQ 75MG BASEM
 EQ 150MG BASEM

N62910 001
 JUL 05, 1988
 N62910 002
 JUL 05, 1988

CHLORTHALIDONE

TABLET; ORAL
 CHLORTHALIDONE
 > ADD > AB PIONEER PHARMS 50MG
 > ADD >

N89591 001
 JUL 21, 1988

CLINDAMYCIN PHOSPHATE

INJECTABLE; IM-IV
 CLINDAMYCIN PHOSPHATE
 AP LOCH PHARMS

EQ 150MG BASE/MLM

N62905 001
 MAY 09, 1988

CHLORZOXAZONE

TABLET; ORAL
 CHLORZOXAZONE
 AA BARR LABS 500MG
 AA CORD LABS 250MG
 AA LEMMON 500MG
 AA LEMMON 500MG
 AA PARAFON FORTE DSC
 MCNEIL PHARM 500MG

N89895 001
 MAY 04, 1988
 N89852 001
 MAY 04, 1988
 N89853 001
 MAY 04, 1988
 N89859 001
 MAY 04, 1988

N11529 002
 JUN 15, 1987

INJECTABLE; INJECTION
 CLINDAMYCIN PHOSPHATE
 AP ELKINS SINN

EQ 150MG BASE/MLM

N62953 001
 APR 21, 1988

AP LEDERLE PARNTLS

EQ 150MG BASE/MLM

N62889 001
 APR 25, 1988

AP LEMMON

EQ 150MG BASE/MLM

N62900 001
 JUN 08, 1988

AP LYPHOMED

EQ 150MG BASE/MLM

N62747 001
 JUN 03, 1988

AP QUAD PHARMS

EQ 150MG BASE/MLM

N62877 001
 MAR 15, 1988

AP SOLOPAK LABS

EQ 150MG BASE/MLM

N62819 001
 MAR 15, 1988

AP

EQ 150MG BASE/MLM

N62852 001
 MAR 17, 1988

8

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / JAN'88 - JUL'88

9

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE
 AB CORD LABS 500MG
 N72191 001
 MAY 02, 1988

CLOMIPHENE CITRATE

TABLET; ORAL
 DLT > /CLONIDINE CITRATE/
 DLT > /AB/ /PLANTEX/ /50MG/
 DLT > /N18361/001/
 > ADD > /MAR/22/1982/
 > ADD > AB SEROPHENE
 > ADD > AB SERONO LABS 50MG
 > ADD > N18361 001
 MAR 22, 1982

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL
 AB LEDERLE LABS 0.1MG
 N71783 001
 APR 05, 1988
 AB 0.2MG
 N71784 001
 APR 05, 1988
 AB 0.3MG
 N71785 001
 APR 05, 1988
 AB WARNER CHILCOTT 0.1MG
 N72138 001
 JUN 13, 1988
 AB 0.2MG
 N72139 001
 JUN 13, 1988
 AB 0.3MG
 N72140 001
 JUN 13, 1988

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM
 AB CHELSEA LABS 3.75MG
 N71878 001
 MAR 15, 1988
 AB 7.5MG
 N71879 001
 MAR 15, 1988
 AB 15MG
 N71860 001
 MAR 15, 1988
 AB PUREPAC PHARM 3.75MG
 N71924 001
 APR 25, 1988
 AB 7.5MG
 N71925 001
 APR 25, 1988
 AB 15MG
 N71926 001
 APR 25, 1988

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM
 AB WARNER CHILCOTT 3.75MG
 N71774 001
 MAR 01, 1988
 AB 7.5MG
 N71775 001
 MAR 01, 1988
 AB 15MG
 N71776 001
 MAR 01, 1988

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM
 AB WARNER CHILCOTT 3.75MG
 N71828 001
 MAR 03, 1988

AB 7.5MG
 N71829 001
 MAR 03, 1988
 AB 15MG
 N71830 001
 MAR 03, 1988
 AB WATSON LABS 3.75MG
 N71852 001
 FEB 09, 1988
 AB 7.5MG
 N71853 001
 FEB 09, 1988
 AB 15MG
 N71854 001
 FEB 09, 1988

GEN-MENE
 AB ALRA LABS 3.75MG
 N71787 001
 APR 26, 1988
 AB 7.5MG
 N71788 001
 APR 26, 1988
 AB 15MG
 N71789 001
 APR 26, 1988

CLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL
CLOXACILLIN SODIUM
 AA BIOCRRAFT LABS EQ 125MG BASE/5ML
 /AB/ /EQ 125MG BASE/5ML/ N62268 001
 /N62268/001/
 TEGOPEN
 AA BRISTOL LABS EQ 125MG BASE/5ML
 /AB/ /EQ 125MG BASE/5ML/ N50192 001
 /AB/ /EQ 125MG BASE/5ML/ N61453 001
 /N50192/001/
 /N61453/001/

COLCHICINE; PROBENECID

TABLET; ORAL
 PROBENECID AND COLCHICINE
 /BP/ /BEECHAM LABS/ /0.5MG;500MG/ N84321 001
 @ BEECHAM LABS 0.5MG;500MG

COLCHICINE; PROBENECID

TABLET; ORAL
PROBENECID W/ COLCHICINE
/BP/ /LEDERLE/LABS/ /0.5MG;500MG/ /N86954/001/
3 LEDERLE LABS 0.5MG;500MG N86954 001

DD > COPPER

DD > INTRAUTERINE DEVICE; INTRAUTERINE
DD > INTRAUTERINE COPPER CONTRACEPTIVE
DD > POPULATION COUNCIL APPROX 176MG COPPERM N18680 002
DD > APR 29, 1988

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL
AB DANBURY PHARMA 10MG N71611 001
MAY 03, 1989 : FEB 29, 1988
AB FLEXERTL 10MG N17821 002
MS&D

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE
QUAD PHARMS 500MG/VIAL N71563 001
MAY 06, 1988

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
AB CORD LABS 10MG N72099 001
MAY 24, 1988
AB 25MG N72100 001
MAY 24, 1988
AB 50MG N72101 001
MAY 24, 1988
AB 75MG N72102 001
JUN 20, 1988
AB 100MG N72103 001
JUN 20, 1988
AB 150MG N72104 001
JUN 20, 1988

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
AB VITARINE 10MG N72167 001
FEB 03, 1988
AB 150MG N72254 001
FEB 03, 1988
AB NORPRAMIN 10MG N14399 007
FEB 11, 1982
AB 150MG N14399 006

DESONIDE

OINTMENT; TOPICAL
DESONEN
AB OWEN LABS 0.05% N71425 001
JUN 15, 1988
AB TRIDESTILON 0.05% N17426 001
MILES PHARM

DESOXYCORTICOSTERONE ACETATE

PELLET; IMPLANTATION
PERCORTEN
> DLT > /CIBA/PHARM/ /125MG/ /N85151/001/
> ADD > 3 CIBA PHARM 125MG N05151 001

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE
/BP/ /BARR/LABS/ /0.25MG/ /N84613/001/
/BP/ /0.25MG/ /N84764/001/
/BP/ /0.5MG/ /N84884/001/
/BP/ /0.75MG/ /N84881/001/
/BP/ /0.75MG/ /N84765/001/
/BP/ /1.5MG/ /N84886/001/
/BP/ /1.5MG/ /N84763/001/
3 BARR LABS 0.25MG N84013 001
3 0.25MG N84764 001
3 0.5MG N84084 001
3 0.75MG N84081 001
3 0.75MG N84765 001
3 1.5MG N84086 001
3 1.5MG N84763 001

DEXTROSEINJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER
 AP KENDALL MCGAN 10GM/100MLM N19626 004
 FEB 02, 1988

DEXTROSE 2.5% IN PLASTIC CONTAINER
 KENDALL MCGAN 2.5GM/100MLM N19626 001
 FEB 02, 1988

DEXTROSE 5% IN PLASTIC CONTAINER
 AP KENDALL MCGAN 5GM/100MLM N19626 002
 FEB 02, 1988

DEXTROSE 7.7% IN PLASTIC CONTAINER
 KENDALL MCGAN 7.7GM/100MLM N19626 003
 FEB 02, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
 /ABBOTT/LAB/ 5GM/100ML; 14.5MG/100ML; 130MG/100ML N18876/001/
 JAN/17/1986/

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
 /ABBOTT/LAB/ 5GM/100ML; 14.5MG/100ML; 130MG/100ML N18876/002/
 JAN/17/1986/

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% AND POTASSIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 /ABBOTT/LAB/ 5GM/100ML; 14.5MG/100ML; 130MG/100ML N18876/003/
 JAN/17/1986/

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
 /ABBOTT/LAB/ 5GM/100ML; 15.0MG/100ML; 125MG/100ML N18365/001/
 JAN/17/1986/

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
 /ABBOTT/LAB/ 5GM/100ML; 14.5MG/100ML; 130MG/100ML N18362/002/
 JAN/17/1986/

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 /ABBOTT/LAB/ 5GM/100ML; 14.5MG/100ML; 130MG/100ML N18362/003/
 JAN/17/1986/

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 37MG/100ML; 200MG/100ML N19630 031
 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 37MG/100ML; 450MG/100ML N19630 037
 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 37MG/100ML; 900MG/100ML N19630 043
 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 37MG/100ML; 110MG/100ML N19630 001
 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 37MG/100ML; 200MG/100ML N19630 007
 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 37MG/100ML; 330MG/100ML N19630 013
 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 37MG/100ML; 450MG/100ML N19630 019
 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 37MG/100ML; 900MG/100ML N19630 025
 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 37MG/100ML; 700MG/100ML N19630 032
 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 75MG/100ML; 450MG/100ML N19630 038
 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 75MG/100ML; 900MG/100ML N19630 044
 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.2% IN PLASTIC CONTAINER
 AP KENDALL MCGAN 5GM/100ML; 75MG/100ML;
 200MG/100ML N19630 008
 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.33% IN PLASTIC CONTAINER
 AP KENDALL MCGAN 5GM/100ML; 75MG/100ML;
 330MG/100ML N19630 014
 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP KENDALL MCGAN 5GM/100ML; 75MG/100ML;
 450MG/100ML N19630 020
 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.9% IN PLASTIC CONTAINER
 AP KENDALL MCGAN 5GM/100ML; 75MG/100ML;
 900MG/100ML N19630 026
 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM
 CHLORIDE 0.11% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 75MG/100ML;
 110MG/100ML N19630 002
 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM
 CHLORIDE 0.2% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 110MG/100ML;
 200MG/100ML N19630 033
 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM
 CHLORIDE 0.45% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 110MG/100ML;
 450MG/100ML N19630 039
 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM
 CHLORIDE 0.9% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 110MG/100ML;
 900MG/100ML N19630 045
 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM
 CHLORIDE 0.11% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 110MG/100ML;
 110MG/100ML N19630 003
 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM
 CHLORIDE 0.2% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 110MG/100ML;
 200MG/100ML N19630 009
 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.33% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 110MG/100ML;
 330MG/100ML N19630 015
 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM
 CHLORIDE 0.45% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 110MG/100ML;
 450MG/100ML N19630 021
 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM
 CHLORIDE 0.9% IN PLASTIC CONTAINER
 KENDALL MCGAN 5GM/100ML; 110MG/100ML;
 900MG/100ML N19630 027
 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM
 CHLORIDE 0.2% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 150MG/100ML;
 200MG/100ML N19630 034
 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM
 CHLORIDE 0.45% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 150MG/100ML;
 450MG/100ML N19630 040
 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM
 CHLORIDE 0.9% IN PLASTIC CONTAINER
 KENDALL MCGAN 10GM/100ML; 150MG/100ML;
 900MG/100ML N19630 046
 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.2% IN PLASTIC CONTAINER
 AP KENDALL MCGAN 5GM/100ML; 150MG/100ML;
 200MG/100ML N19630 010
 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.33% IN PLASTIC CONTAINER
 AP KENDALL MCGAN 5GM/100ML; 150MG/100ML;
 330MG/100ML N19630 016
 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP KENDALL MCGAN 5GM/100ML; 150MG/100ML;
 450MG/100ML N19630 022
 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTIONPOTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP KENDALL MCGAN 5GM/100ML;150MG/100ML;
900MG/100MLM N19630 028
FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

KENDALL MCGAN 5GM/100ML;150MG/100ML;
110MG/100MLM N19630 004
FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAN 10GM/100ML;220MG/100ML;
200MG/100MLM N19630 035
FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

KENDALL MCGAN 10GM/100ML;220MG/100ML;
450MG/100MLM N19630 041
FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

KENDALL MCGAN 10GM/100ML;220MG/100ML;
900MG/100MLM N19630 047
FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

KENDALL MCGAN 5GM/100ML;220MG/100ML;
110MG/100MLM N19630 005
FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAN 5GM/100ML;220MG/100ML;
200MG/100MLM N19630 011
FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

KENDALL MCGAN 5GM/100ML;220MG/100ML;
330MG/100MLM N19630 017
FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

KENDALL MCGAN 5GM/100ML;220MG/100ML;
450MG/100MLM N19630 023
FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

KENDALL MCGAN 5GM/100ML;220MG/100ML;
900MG/100MLM N19630 029
FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTIONPOTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAN 10GM/100ML;300MG/100ML;
200MG/100MLM N19630 036
FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

KENDALL MCGAN 10GM/100ML;300MG/100ML;
450MG/100MLM N19630 042
FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

KENDALL MCGAN 10GM/100ML;300MG/100ML;
900MG/100MLM N19630 048
FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP KENDALL MCGAN 5GM/100ML;300MG/100ML;
200MG/100MLM N19630 012
FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP KENDALL MCGAN 5GM/100ML;300MG/100ML;
330MG/100MLM N19630 018
FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP KENDALL MCGAN 5GM/100ML;300MG/100ML;
450MG/100MLM N19630 024
FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP KENDALL MCGAN 5GM/100ML;300MG/100ML;
900MG/100MLM N19630 030
FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

KENDALL MCGAN 5GM/100ML;300MG/100ML;
110MG/100MLM N19630 006
FEB 17, 1988

POTASSIUM CHLORIDE 10MG IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;74.5MG/100ML;
450MG/100MLM N18362 009
JUL 05, 1983

AP 5GM/100ML;149MG/100ML;
450MG/100MLM N18362 005
MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTIONPOTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;74.5MG/100ML;
900MG/100ML N19691 002
MAR 24, 1988

AP 5GM/100ML;149MG/100ML;
900MG/100ML N19691 004
MAR 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;74.5MG/100ML;
225MG/100ML N18365 002
JUL 05, 1983

5GM/100ML;149MG/100ML;
225MG/100ML N18365 006
MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;74.5MG/100ML;
300MG/100ML N18876 001
JAN 17, 1986

5GM/100ML;149MG/100ML;
300MG/100ML N18876 006
MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.9% IN PLASTIC CONTAINER

AP TRAVENOL LABS 5GM/100ML;75MG/100ML;
900MG/100ML N19308 004
APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;224MG/100ML;
450MG/100ML N18362 006
MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;224MG/100ML;
900MG/100ML N19691 006
MAR 24, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;224MG/100ML;
225MG/100ML N18365 008
MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;224MG/100ML;
300MG/100ML N18876 007
MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTIONPOTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;149MG/100ML;
450MG/100ML N18362 010
JUL 05, 1983

AP 5GM/100ML;298MG/100ML;
450MG/100ML N18362 007
MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;149MG/100ML;
900MG/100ML N19691 005
MAR 24, 1988

AP 5GM/100ML;298MG/100ML;
900MG/100ML N19691 008
MAR 24, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;149MG/100ML;
225MG/100ML N18365 001

5GM/100ML;298MG/100ML;
225MG/100ML N18365 009
MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;298MG/100ML;
300MG/100ML N18876 008
MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;149MG/100ML;
300MG/100ML N18876 002
JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;224MG/100ML;
450MG/100ML N18362 002

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;224MG/100ML;
900MG/100ML N19691 007
MAR 24, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUMCHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;224MG/100ML;
225MG/100ML N18365 003
JUL 05, 1983

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / JAN'88 - JUL'88

15

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.3% IN PLASTIC CONTAINERABBOTT LABS 5GM/100ML;224MG/100ML;
300MG/100ML N18876 003
JAN 17, 1986POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.9% IN PLASTIC CONTAINERAP TRAVENOL LABS 5GM/100ML;224MG/100ML;
900MG/100ML N19308 006
APR 05, 1985POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.45% IN PLASTIC CONTAINERAP ABBOTT LABS 5GM/100ML;298MG/100ML;
450MG/100ML N18362 003POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.9% IN PLASTIC CONTAINERAP ABBOTT LABS 5GM/100ML;298MG/100ML;
900MG/100ML N19691 009
MAR 24, 1988POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.225% IN PLASTIC CONTAINERABBOTT LABS 5GM/100ML;298MG/100ML;
225MG/100ML N18365 004
JUL 05, 1983POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM
CHLORIDE 0.3% IN PLASTIC CONTAINERABBOTT LABS 5GM/100ML;298MG/100ML;
300MG/100ML N18876 004
MAR 28, 1988POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE
0.45% IN PLASTIC CONTAINERAP ABBOTT LABS 5GM/100ML;74.5MG/100ML;
450MG/100ML N18362 008
MAR 28, 1988AP 5GM/100ML;149MG/100ML;
450MG/100ML N18362 004
MAR 28, 1988POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE
0.9% IN PLASTIC CONTAINERAP ABBOTT LABS 5GM/100ML;74.5MG/100ML;
900MG/100ML N19691 001
MAR 24, 1988AP 5GM/100ML;149MG/100ML;
900MG/100ML N19691 003
MAR 24, 1988DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE
0.225% IN PLASTIC CONTAINERABBOTT LABS 5GM/100ML;74.5MG/100ML;
225MG/100ML N18365 005
MAR 28, 19885GM/100ML;149MG/100ML;
225MG/100ML N18365 007
MAR 28, 1988POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE
0.3% IN PLASTIC CONTAINERABBOTT LABS 5GM/100ML;74.5MG/100ML;
300MG/100ML N18876 005
MAR 28, 19885GM/100ML;149MG/100ML;
300MG/100ML N18876 009
MAR 28, 1988DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC
CONTAINERKENDALL MCGAW 10GM/100ML;110MG/100ML N19631 011
FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;200MG/100ML N19631 012
FEB 24, 1988DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC
CONTAINERKENDALL MCGAW 10GM/100ML;330MG/100ML N19631 013
FEB 24, 1988DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
CONTAINERKENDALL MCGAW 10GM/100ML;450MG/100ML N19631 014
FEB 24, 1988DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP KENDALL MCGAW 10GM/100ML;900MG/100ML N19631 015
FEB 24, 1988DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
CONTAINERKENDALL MCGAW 2.5GM/100ML;
110MG/100ML N19631 001
FEB 24, 1988DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC
CONTAINERKENDALL MCGAW 2.5GM/100ML;
200MG/100ML N19631 002
FEB 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC

CONTAINER

KENDALL MCGAN

2.5GM/100ML;

330MG/100MLM

N19631 003

FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC

CONTAINER

AP

KENDALL MCGAN

2.5GM/100ML;

450MG/100MLM

N19631 004

FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC

CONTAINER

KENDALL MCGAN

2.5GM/100ML;

900MG/100MLM

N19631 005

FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

KENDALL MCGAN

5GM/100ML;110MG/100MLM

N19631 006

FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP

KENDALL MCGAN

5GM/100ML;200MG/100MLM

N19631 007

FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.35% IN PLASTIC CONTAINER

AP

KENDALL MCGAN

5GM/100ML;330MG/100MLM

N19631 008

FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP

KENDALL MCGAN

5GM/100ML;450MG/100MLM

N19631 009

FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP

KENDALL MCGAN

5GM/100ML;900MG/100MLM

N19631 010

FEB 24, 1988

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOCAL-76

AP

SQUIBB DIAGS

66%;10%M

N89347 001

JUN 01, 1988

DIAZEPAM

TABLET; ORAL

9-PAM

AB

QUANTUM PHARMS

2MG

N72431 001

APR 29, 1988

AB

5MG

N72432 001

APR 29, 1988

AB

10MG

N72433 001

APR 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

> ADD >

MED MRKTG SPECLTIES

50MG

N17425 001

> ADD >

3

100MG

N17425 002

> DLT >

/S/SCHERING/

/50MG/

/N17425/001/

INJECTABLE; INJECTION

DIAZOXIDE

AP

QUAD PHARMS

15MG/MLM

N71908 001

JAN 26, 1988

SUSPENSION; ORAL

PROGLYCEM

> ADD >

MED MRKTG SPECLTIES

50MG/ML

N17453 001

> DLT >

/S/SCHERING/

/50MG/ML/

/N17453/001/

> ADD >

DICLOFENAC SODIUM

> ADD >

TABLET, ENTERIC COATED; ORAL

> ADD >

VOLTAREN

> ADD >

CIBA PHARM

25MG

N19201 001

> ADD >

50MG

JUL 28, 1988

> ADD >

50MG

N19201 002

> ADD >

75MG

JUL 28, 1988

> ADD >

75MG

N19201 003

> ADD >

75MG

JUL 28, 1988

DIETHYLCARBAMAZINE CITRATE

TABLET; ORAL

HETRAZAN

> DLT >

/LEDERLE/LABS/

/50MG/

/N06459/001/

> ADD >

3 LEDERLE LABS

50MG

N06459 001

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP

BAXTER

80MG/100ML

N19615 001

MAR 27, 1987

AP

160MG/100ML

N19615 002

MAR 27, 1987

AP

320MG/100ML

N19615 003

MAR 27, 1987

640MG/100ML

N19615 004

MAR 27, 1987

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

/60/	/TRAVENOL LABS/	/40MG/100ML/	/N19615/001/
			/MAR/27/1987/
/60/		/160MG/100ML/	/N19615/002/
			/MAR/27/1987/
/60/		/320MG/100ML/	/N19615/003/
			/MAR/27/1987/
		/640MG/100ML/	/N19615/004/
			/MAR/27/1987/

DOXEPTIN HYDROCHLORIDE

CAPSULE; ORAL

ADAPIN

AB	PENNAULT	EQ 150MG BASE	N16987 007
			APR 13, 1987

DOXEPTIN HCL

AB	BARR LABS	EQ 25MG BASEM	N71502 001
			FEB 18, 1988
AB		EQ 50MG BASEM	N71653 001
			FEB 18, 1988
AB		EQ 75MG BASEM	N71654 001
			FEB 18, 1988
AB		EQ 100MG BASEM	N71521 001
			FEB 18, 1988
AB	CHELSEA LABS	EQ 75MG BASEM	N71763 001
			FEB 09, 1988
AB		EQ 150MG BASEM	N71764 001
			FEB 09, 1988
AB	LEDERLE LABS	EQ 10MG BASEM	N71685 001
			JAN 05, 1988
AB		EQ 25MG BASEM	N71686 001
			JAN 05, 1988
AB		EQ 50MG BASEM	N71673 001
			JAN 05, 1988
AB		EQ 75MG BASEM	N71674 001
			JAN 05, 1988
AB		EQ 100MG BASEM	N71675 001
			JAN 05, 1988
AB		EQ 150MG BASEM	N71676 001
			JAN 05, 1988

CONCENTRATE; ORAL

DOXEPTIN HCL

> ADD >	AA	MY K LABS	EQ 10MG BASE/MLM	N71918 001
> ADD >				JUL 20, 1988

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB	VITARINE	EQ 50MG BASEM	N62780 001
			APR 12, 1988

INJECTABLE; INJECTION

DOXYCYCLINE

AP	BEN VENUE LABS	EQ 100MG BASE/VIALM	N62569 001
			MAR 09, 1988
AP		EQ 200MG BASE/VIALM	N62569 002
			MAR 09, 1988

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

AP	ABBOTT LABS	2.5MG/MLM	N71981 001
			FEB 29, 1988
AP	DUPONT CRI CARE	2.5MG/MLM	N71645 001
			APR 07, 1988

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

AP	ABBOTT LABS	2.5MG/ML;	
		EQ 0.05MG BASE/MLM	N71982 001
			MAY 04, 1988

INNOVAR

AP	JANSSEN PHARMA	2.5MG/ML;	
		EQ 0.05MG BASE/MLM	N16049 001

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

REVERSOL

AP	ORGANON	10MG/MLM	N89624 001
			MAY 13, 1988

ENALAPRIL MALEATE

TABLET; ORAL

VASOTEC

> ADD >		MS&D RES LABS	2.5MG	N18998 005
> ADD >				JUL 26, 1988

ENALAPRILATINJECTABLE; INJECTION
VASOTEC

MS&D RES LABS 1.25MG/MLM

N19309 001
FEB 09, 1988EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINEAP ABBOTT LABS 0.005MG/ML;0.5%_mN89635 001
JUN 21, 1988AP 0.005MG/ML;1%_mN89649 001
JUN 21, 1988AP 0.005MG/ML;1.5%_mN89645 001
JUN 21, 1988AP 0.005MG/ML;1.5%_mN89650 001
JUN 21, 1988AP 0.005MG/ML;2%_mN89651 001
JUN 21, 1988AP 0.01MG/ML;1%_mN89644 001
JUN 21, 1988AP 0.01MG/ML;2%_mN89646 001
JUN 21, 1988OCTOCAINE/AP/ NOVOCOL/CHEN/
AP NOVOCOL PHARM/0.01MG/ML;2%_m

/N84048/001/

/AP/ NOVOCOL PHARM

/0.01MG/ML;2%_m

/N84048 001

/AP/ NOVOCOL PHARM

/0.02MG/ML;2%_m

/N84048/002/

XYLOCAINE H/ EPINEPHRINEAP ASTRA PHARM PRODS 0.005MG/ML;0.5%_mN06488 013
NOV 13, 1986AP 0.005MG/ML;1%_mN06488 018
NOV 13, 1986AP 0.005MG/ML;2%_mN06488 019
NOV 13, 1986ERGOLOID MESYLATES

TABLET; ORAL

/AB/ ERGOLOID MESYLATES/
/AB/ CHELSEA LABS/

/1MG/

/N88207/001/
/MAR 22, 1984/GERMAL

AB CHELSEA LABS 1MG

N88207 001
MAR 22, 1984ERGOLOID MESYLATES

TABLET; SUBLINGUAL

GIRCANOL/AB/ RIKER LABS/
/AB/ RIKER LABS/0.5MG/
/1MG//N84868/001/
/N84868/001/

3 RIKER LABS

0.5MG
1MGN84868 001
N85809 001ERGOLOID MESYLATES/AB/ ERGOLOID MESYLATES/
/AB/ CHELSEA LABS//0.5MG/
/1MG//N86189/001/
/N86189/001/GERMALAA CHELSEA LABS
AA0.5MG
1MGN86189 001
N86188 001ERYTHROMYCIN

SOLUTION; TOPICAL

ETS-22

AT PADDOCK LABS

2%_mN62687 001
FEB 05, 1988ERYTHROMYCIN> ADD > AT NASKA PHARMA
> ADD >2%_mN62957 001
JUL 21, 1988ERYTHROMYCIN ETHYLSUCCINATE

TABLET, CHEWABLE; ORAL

ERYPED> ADD >
> ADD > AB

ABBOTT LABS

EQ 200MG BASEM

N50297 003
JUL 05, 1988ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

AB BARR LABS

EQ 200MG BASE/5 ML;
EQ 600MG BASE/5MLMN62759 001
MAY 20, 1988ERYZOLE

AB ALRA LABS

EQ 200MG BASE/5ML;
EQ 600MG BASE/5MLMN62758 001
JUN 15, 1988PEDIAZOLE

AB ROSS LABS

EQ 200MG BASE/5ML;
EQ 600MG BASE/5MLM

N50529 001

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIH

AP	ABBOTT LABS	EQ 500MG BASE/VIALM	N62586 001
			JAN 04, 1988
AP		EQ 1GM BASE/VIALM	N62586 002
			JAN 04, 1988

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

/AB/	/BRISTOL/LABS/	/EQ 250MG BASE/	/N61304/001/
/AB/		/EQ 250MG BASE/	/N61304/001/
	3 BRISTOL LABS	EQ 250MG BASE	N61304 001
	3	EQ 250MG BASE	N61887 001

ERYPAR

/AB/	/PARKE/DAVIS/	/EQ 250MG BASE/	/N62032/001/
/AB/		/EQ 500MG BASE/	/N62032/002/
	3 PARKE DAVIS	EQ 250MG BASE	N62032 001
	3	EQ 500MG BASE	N62032 002

ERYTHROCIH STEARATE

/AB/	/ABBOTT/LABS/	/EQ 125MG BASE/	/N60359/001/
	3 ABBOTT LABS	EQ 125MG BASE	N60359 002

ERYTHROMYCIN STEARATE

/AB/	/LEDERLE/LABS/	/EQ 250MG BASE/	/N62089/001/
/AB/		/EQ 500MG BASE/	/N62089/002/
	3 LEDERLE LABS	EQ 250MG BASE	N62089 001
	3	EQ 500MG BASE	N62089 002

PFIZER-E

/AB/	/PFIZER/LABS/	/EQ 500MG BASE/	/N61791/001/
	3 PFIZER LABS	EQ 500MG BASE	N61791 002

ESTRONE

INJECTABLE; INJECTION

ESTRONE

> DLT >	/BP/	/STERIS/LABS/	/5MG/ML/	/N85239/001/
> ADD >		STERIS LABS	5MG/ML	N85239 001
		THEELIN		
> DLT >	/BP/	/PARKE/DAVIS/	/1MG/ML/	/N03977/001/
> DLT >	/BP/		/5MG/ML/	/N03977/003/
> ADD >		3 PARKE DAVIS	1MG/ML	N03977 001
> ADD >		3	5MG/ML	N03977 003

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

AB	SEARLE PHARMS	0.035MG;1MG	N71480 001
			APR 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.035MG;0.5MG AND 1MG	N71043 001
			APR 01, 1988

ORTHO-NOVUM 10/11-21

AB	ORTHO PHARM	0.035MG;0.5MG AND 1MG	N18354 001
			JAN 11, 1982

TABLET; ORAL-28

NORETHIN 1/35E-28

AB	SEARLE PHARMS	0.035MG;1MG	N71481 001
			APR 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.035MG;0.5MG AND 1MG	N71044 001
			APR 01, 1988

ORTHO-NOVUM 10/11-28

AB	ORTHO PHARM	0.035MG;0.5MG AND 1MG	N18354 002
			JAN 11, 1982

ETHIODIZED OIL

> DLT >	/INJECTABLE; INJECTION/		
> DLT >	/ETHIODOL/		
> DLT >	/FOUGERA/	/99%/	/N09190/001/
> ADD >	OIL; INTRALYMPHATIC, INTRAUTERINE		
> ADD >	ETHIODOL		
> ADD >	FOUGERA	99%	N09190 001

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

> ADD >	AB	HALSEY DRUG	EQ 200MG BASEM	N72355 001
> ADD >			AUG 17, 1988 : JUL 05, 1988	
> ADD >	AB		EQ 300MG BASEM	N72356 001
> ADD >			AUG 17, 1988 : JUL 05, 1988	
	AB	QUANTUM PHARMCS	EQ 200MG BASEM	N72214 001
			AUG 17, 1988 : APR 14, 1988	
	AB		EQ 300MG BASEM	N71738 001
			AUG 17, 1988 : APR 14, 1988	

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

> ADD > AB	WATSON LABS	EQ 200MG BASEM	N72294 001
> ADD >		AUG 17, 1988 : JUL 08, 1988	
> ADD > AB		EQ 300MG BASEM	N72293 001
> ADD >		AUG 17, 1988 : JUL 08, 1988	
	<u>NALFON</u>		
AB	DISTA PRODS	EQ 300MG BASE	N17604 002
	<u>NALFON 200</u>		
AB	DISTA PRODS	EQ 200MG BASE	N17604 003

TABLET; ORAL

FENOPROFEN CALCIUM

AB	AM THERPTCS	EQ 600MG BASEM	N72309 001
		AUG 17, 1988 : JUN 16, 1988	
AB	CHELSEA LABS	EQ 600MG BASEM	N72407 001
		AUG 17, 1988 : JUN 13, 1988	
> ADD > AB	HALSEY DRUG	EQ 600MG BASEM	N72357 001
> ADD >		AUG 17, 1988 : JUL 05, 1988	
AB	LEDERLE LABS	EQ 600MG BASEM	N72326 001
		AUG 17, 1988 : APR 20, 1988	
AB	MYLAN PHARMS	EQ 600MG BASEM	N72267 001
		AUG 17, 1988 : JUN 08, 1988	
> ADD > AB	PAR PHARM	EQ 600MG BASEM	N72429 001
> ADD >		AUG 17, 1988 : JUL 19, 1988	
AB	PHARM BASICS	EQ 600MG BASEM	N72362 001
		AUG 17, 1988 : JUN 16, 1988	
AB	PUREPAC PHARM	EQ 600MG BASEM	N72274 001
		MAY 02, 1988	
AB	QUANTUM PHARMCS	EQ 600MG BASEM	N72194 001
		AUG 17, 1988 : APR 14, 1988	
> ADD > AB	WATSON LABS	EQ 600MG BASEM	N72165 001
> ADD >		AUG 17, 1988 : JUL 08, 1988	
	<u>NALFON</u>		
AB	DISTA PRODS	EQ 600MG BASE	N17710 001

FLECAINIDE ACETATE

TABLET; ORAL

TAMBOCOR
RIKER LABS

150MG
N18830 003
JUN 03, 1988

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

> ADD > AT	G&N LABS	0.025% N89525 001	JUL 26, 1988
> ADD >			

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

> ADD > AT	G&N LABS	0.01% N89526 001	JUL 26, 1988
> ADD >			

OIL; TOPICAL

DERMA-SMOOTH/FS
HILL DERM

0.01%
N19452 001
FEB 03, 1988

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

> ADD > AT	G&N LABS	0.025% N89524 001	JUL 26, 1988
> ADD >			

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB	CLAY PARK LABS	0.05% N71790 001	JUL 13, 1988 : APR 25, 1988
----	----------------	---------------------	-----------------------------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	BEN VENUE LABS	50MG/ML N89508 001	JAN 26, 1988
----	----------------	-----------------------	--------------

FLUPHENAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

FLUPHENAZINE HCL

AP	QUAD PHARMS	2.5MG/ML N89800 001	JUN 08, 1988
----	-------------	------------------------	--------------

TABLET; ORAL

PERMITIL
1/2 SCHERING
1/2
1/2
1/2

BP	SCHERING	2.5MG	N12034 004
BP		5MG	N12034 005
BP		10MG	N12034 006

N12034/004/
N12034/005/
N12034/006/
N12034 004
N12034 005
N12034 006

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HCL

AB HALSEY DRUG 15MG

N71808 001

JAN 07, 1988

AB 30MG

N71809 001

JAN 07, 1988

FOLIC ACID

TABLET; ORAL

FOLIC ACID

/AA/ /BARR/LABS/ 1MG

3 BARR LABS 1MG

/N89177/001/

/JAN/88:/1988/

N89177 001

JAN 08, 1986

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

/AP/ /PARKE/DAVIS/ 10MG/ML

AP WARNER CHILCOTT 10MG/ML

/N18420/001/

/FEB/26:/1982/

N18420 001

FEB 26, 1982

TABLET; ORAL

FUROSEMIDE

AB BARR LABS 80MG

N70100 001

JAN 26, 1988

AB DANBURY PHARMA 80MG

N71594 001

FEB 09, 1988

GADOPENTETATE DIMETHYLAMINE

INJECTABLE; INJECTION

MAGNEVIST

BERLEX LABS

469.01MG/ML

N19596 001

JUN 02, 1988

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

/MEDI/PHYSICS/

3 MEDI PHYSICS

/1MCI/ML/

1MCI/ML

/N17700/001/

N17700 001

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

PRED-G

ALLERGAN PHARMS

EQ 0.3% BASE; 1/2M

N50586 001

JUN 10, 1988

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP ABBOTT LABS

0.2MG/ML

N89393 001

JUN 15, 1988

HALOPERIDOL

TABLET; ORAL

HALDOL SOLUTAB

/3/MCNEIL/LABS/

3 MCNEIL PHARM

HALOPERIDOL

AB BARR LABS

/1MG/

1MG

/N17079/001/

N17079 001

AB 5MG

N71212 001

JAN 07, 1988

AB 10MG

N71173 001

JAN 07, 1988

AB 20MG

N71177 001

JAN 07, 1988

AB BOLAR PHARM 0.5MG

N71571 001

JUN 03, 1988

AB 1MG

N71572 001

JUN 03, 1988

AB 2MG

N71573 001

JUN 03, 1988

AB 5MG

N71374 001

JUN 03, 1988

AB 10MG

N71375 001

JUN 03, 1988

AB 20MG

N71376 001

JUN 03, 1988

AB CORD LABS 10MG

N71210 001

MAR 11, 1988

AB 20MG

N71211 001

MAR 11, 1988

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

/AA/ /MCNEIL/LABS/

AA MCNEIL PHARM

/EQ 2MG BASE/ML/

EQ 2MG BASE/ML

/N15922/001/

N15922 001

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

<u>AA</u>	<u>HALOPERIDOL INTENSOL</u> ROXANE LABS	<u>EQ 3MG BASE/MLM</u>	N72045 001 APR 12, 1988
-----------	--	------------------------	----------------------------

INJECTABLE; INJECTION

<u>AP</u>	<u>HALOPERIDOL</u> LEMMON	<u>EQ 5MG BASE/MLM</u>	N70713 001 MAY 17, 1988
<u>AP</u>		<u>EQ 5MG BASE/MLM</u>	N70714 001 MAY 17, 1988
<u>AP</u>		<u>EQ 5MG BASE/MLM</u>	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION

> DLT >	<u>HEPARIN LOCK FLUSH</u>		
> ADD >	<u>ABBOTT LABS</u>	<u>/100 UNITS/ML/</u>	<u>/N05264/010/</u>
> ADD >	3 ABBOTT LABS	100 UNITS/ML	N05264 010
> ADD >	<u>HEPARIN LOCK FLUSH IN PLASTIC CONTAINER</u>		
> ADD >	<u>ABBOTT LABS</u>	<u>10 UNITS/ML</u>	<u>N05264 015</u>
> ADD >			MAY 21, 1985
> ADD >	<u>ABBOTT LABS</u>	<u>100 UNITS/ML</u>	<u>N05264 016</u>
> ADD >			MAY 21, 1985

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC

<u>AP</u>	<u>CONTAINER</u> <u>ABBOTT LABS</u>	<u>/10,000 UNITS/100ML/</u>	<u>/N19339/003/</u>
			<u>/MAR/27./1985/</u>
	3 ABBOTT LABS	10,000 UNITS/100ML	N19339 003 MAR 27, 1985

HEPARIN SODIUM 1000 UNITS AND SODIUM CHLORIDE 0.9% IN

<u>AP</u>	<u>PLASTIC CONTAINER</u> BAXTER	<u>200 UNITS/100ML</u>	<u>N18609 001</u>
			APR 28, 1982
<u>AP</u>	<u>TRAVENOL LABS</u>	<u>/100 UNITS/100ML/</u>	<u>/N18609/001/</u>
			<u>/APR/28./1982/</u>

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC

<u>AP</u>	<u>CONTAINER</u> <u>ABBOTT LABS</u>	<u>/5,000 UNITS/100ML/</u>	<u>/N19339/001/</u>
			<u>/MAR/27./1985/</u>
	3 ABBOTT LABS	5,000 UNITS/100ML	N19339 001 MAR 27, 1985

HEPARIN SODIUM 2000 UNITS AND SODIUM CHLORIDE 0.9% IN

<u>AP</u>	<u>PLASTIC CONTAINER</u> BAXTER	<u>200 UNITS/100ML</u>	<u>N18609 002</u>
			APR 28, 1982

HEPARIN SODIUM

INJECTABLE; INJECTION

<u>AP</u>	<u>HEPARIN SODIUM 20,000 UNITS AND SODIUM CHLORIDE 0.9% IN</u> <u>PLASTIC CONTAINER</u>	<u>/100 UNITS/100ML/</u>	<u>/N18609/002/</u>
	<u>TRAVENOL LABS</u>		<u>/APR/28./1982/</u>

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC

<u>AP</u>	<u>CONTAINER</u> <u>ABBOTT LABS</u>	<u>/5,000 UNITS/100ML/</u>	<u>/N19339/004/</u>
			<u>/MAR/27./1985/</u>
<u>AP</u>		<u>/10,000 UNITS/100ML/</u>	<u>/N19339/002/</u>
			<u>/MAR/27./1985/</u>
	3 ABBOTT LABS	5,000 UNITS/100ML	N19339 004 MAR 27, 1985
		10,000 UNITS/100ML	N19339 002 MAR 27, 1985

HEPARIN SODIUM 5000 UNITS AND SODIUM CHLORIDE 0.9% IN

<u>AP</u>	<u>PLASTIC CONTAINER</u> BAXTER	<u>500 UNITS/100ML</u>	<u>N18609 003</u>
			APR 28, 1982
<u>AP</u>	<u>TRAVENOL LABS</u>	<u>/500 UNITS/100ML/</u>	<u>/N18609/003/</u>
			<u>/APR/28./1982/</u>

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

<u>AP</u>	<u>HYDRALAZINE HCL</u> <u>PUREPAC PHARM</u>	<u>/50MG/</u>	<u>/N88178/001/</u>
			<u>/AUG/15./1983/</u>
	3 PUREPAC PHARM	50MG	N88178 001 AUG 15, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

<u>AB</u>	<u>HYDRAL</u> REID ROWELL	<u>25MG;25MG</u>	<u>N87608 001</u>
			FEB 08, 1982
<u>AB</u>		<u>50MG;50MG</u>	<u>N87213 001</u>
			FEB 08, 1982
	<u>/3/</u>	<u>/25MG;25MG/</u>	<u>/N87608/001/</u>
			<u>/FEB/08./1982/</u>
	<u>/3/</u>	<u>/50MG;50MG/</u>	<u>/N87213/001/</u>
			<u>/FEB/08./1982/</u>

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE
/BP/ /REID/ROWELL/ /25MG;15MG;0.1MG/ /N87210/001/
BP REID ROWELL 25MG;15MG;0.1MG N88376 001
OCT 28, 1983
2 25MG;15MG;0.1MG N87210 001
/2/ /25MG;15MG;0.1MG/ /N88376/001/
OCT 28, 1983

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL
HYDROCHLOROTHIAZIDE
AA MY K LABS 50MG/5ML N89661 001
JUN 20, 1988
AA ROXANE LABS 50MG/5ML N88587 001
JUL 02, 1984

TABLET; ORAL
HYDROCHLOROTHIAZIDE
/AB/ /BANMAX/PHARMS/ /25MG/ /N86369/001/
/AB/ /25MG/ /N83554/001/
2 BANMAX PHARMS 25MG N86369 001
2 50MG N83554 001

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL
NORMOZIDE
/SCHERING/ /25MG;400MG/ /N19046/004/
2 SCHERING 25MG;400MG N19046 004
APR 06, 1987
TRANDATE HCT
AB GLAXO 25MG;100MG N19174 001
APR 10, 1987
AB 25MG;200MG N19174 002
APR 10, 1987
AB 25MG;300MG N19174 003
APR 10, 1987
AB 25MG;400MG N19174 004
APR 10, 1987

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL
TRANDATE HCT
/AB/ /GLAXO/ /25MG;100MG/ /N19174/001/
/AB/ /25MG;200MG/ /APR 10, 1987/
/AB/ /25MG;300MG/ /N19174/002/
/AB/ /25MG;400MG/ /APR 10, 1987/
/AB/ /25MG;400MG/ /N19174/003/
/AB/ /25MG;400MG/ /APR 10, 1987/
/AB/ /25MG;400MG/ /N19174/004/
/AB/ /25MG;400MG/ /APR 10, 1987/

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE
AB NOVOPHARM 15MG;250MG N71819 001
APR 08, 1988
AB 25MG;250MG N71820 001
APR 08, 1988
AB 30MG;500MG N71821 001
APR 08, 1988
AB 50MG;500MG N71822 001
APR 08, 1988
/AB/ /PUREPAC/PHARM/ /50MG;500MG/ /N70689/001/
2 PUREPAC PHARM 50MG;500MG N70689 001
APR 24, 1986
AB ZENITH LABS 15MG;250MG N71458 001
MAR 08, 1988
AB 25MG;250MG N71459 001
MAR 08, 1988
AB 30MG;500MG N71460 001
MAR 08, 1988
AB 50MG;500MG N71461 001
MAR 08, 1988

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL
VISKAZIDE
/SANDOZ/PHARMS/ /25MG;5MG/ /N18872/001/
2 SANDOZ PHARMS 25MG;5MG N18872 001
JUL 22, 1987
/AB/ /25MG;10MG/ /N18872/002/
2 25MG;10MG N18872 002
JUL 22, 1987

HYDROCORTISONE

HYDROCORTISONE

/N87795/001/
/NAY/03:/1983/

/dt/ /HYDAG/ /12/
/NFC/LABS/

BETA-HC

N89495 001
JAN 25, 1988

N89705 001
APR 25, 1988

HC (HYDROCORTISONE)

/N80481/001/
 /N80481/002/
 N80481 002

N89704 001
MAR 10, 1988

/BP/ /BARR LABS/ /20MG/ /N83999/001/
2 BARR LABS 20MG N83999 001

HYDROCORTISONE ACETATE

AEROSOL; TOPICAL

24

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%

AI	COPLEY PHARM	1%:1%	N89440 001
			MAY 17, 1988

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AI	STERIS LABS	1%:EQ 3.5MG BASE/ML; 10,000 UNITS/MLM	N62874 001
			MAY 11, 1988

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

/AP/	/ALTANA/	/25MG/ML/	/N87273/001/
			/APR/20/1982/
/AP/		/50MG/ML/	/N87273/002/
			/APR/20/1982/
	3 ALTANA	25MG/ML	N87273 001
			APR 20, 1982
	3	50MG/ML	N87273 002
			APR 20, 1982

SYRUP; ORAL

HYDROXYZINE HCL

AA	NASKA PHARMA	10MG/5MLM	N88785 001
			FEB 03, 1988

TABLET; ORAL

HYDROXYZINE HCL

AB	HALSEY DRUG	10MG	N89366 001
			MAY 02, 1988
AB		25MG	N89117 001
			MAY 02, 1988
AB		50MG	N89396 001
			MAY 02, 1988

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	HALSEY DRUG	800MG	N72137 001
			FEB 05, 1988

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	INVAMED	400MG	N72064 001
			JAN 14, 1988
AB		600MG	N72065 001
			JAN 14, 1988
AB		800MG	N71938 001
			JAN 14, 1988
AB	MEDICOPHARMA	400MG	N71644 001
			FEB 01, 1988
> ADD >	AB	PRIVATE FMTNS	N72300 001
> ADD >	AB	PUREPAC PHARM	N71964 001
			FEB 01, 1988

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE

/AP/	/BANMAX/PHARMS/	/10MG/	/N83827/001/
/AP/		/25MG/	/N83827/002/
/AP/		/50MG/	/N83827/003/
	3 BANMAX PHARMS	50MG	N83827 003
	3	10MG	N83827 001
	3	25MG	N83827 002

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INTRATHECAL

INDIUM IN-111 OXYQUINOLINE

> DLT >	/AMERSHAM/	/N/A/	/N19044/001/
> DLT >			/DEC/23/1985/
> ADD >	AMERSHAM	1MCI/ML	N19044 001
> ADD >			DEC 23, 1985

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB	NOVOPHARM	25MG	N71342 001
			APR 18, 1988
AB		50MG	N71343 001
			APR 18, 1988
> ADD >	AB	VITARINE PHARMS	N71711 001
> ADD >	AB		JUL 05, 1988
> ADD >	AB		N71712 001
> ADD >	AB		JUL 05, 1988

INSULIN PORKINJECTABLE; INJECTION

> DLT >	<u>ILETIN/</u>		
> DLT >	<u>LILLY/</u>		
> ADD >	ILETIN I	500 UNITS/ML	N17931 001
> ADD >	LILLY		

IOHEXOLINJECTABLE; INJECTION

	<u>OMNEPAGUE 100</u>		
	<u>3/STERLING/DRUG/</u>		
AP	STERLING DRUG	38.8%	N18956 001 DEC 26, 1985

IRON DEXTRANINJECTABLE; INJECTION

	<u>PROFERDEX</u>		
> DLT >	<u>3 FISON/</u>		
> ADD >	EQ 50MG IRON/ML		N17807 001

ISONIAZIDTABLET; ORAL

AA	<u>LANTAZID</u>		
	LANNETT	300MG	N89776 001 JUN 13, 1988

ISOSORBIDE DINITRATE

> ADD >	CAPSULE, CONTROLLED RELEASE; ORAL		
> ADD >	ISORDIL		
> ADD >	MYETH-AYERST	40MG	N12882 002 JUL 29, 1988
> ADD >			

ISOSORBIDE DINITRATETABLET; ORAL

> ADD >	<u>ISORDIL</u>		
> ADD >	AB	MYETH-AYERST	5MG
> ADD >	AB		10MG
> ADD >	AB		20MG
> ADD >	AB		30MG
> ADD >	AB		40MG
> ADD >			

ISOSORBIDE DINITRATE

AB	BARR LABS	30MG	N87564 001 SEP 18, 1986
AB	CORD LABS	5MG	N86221 001 JAN 07, 1988
AB		10MG	N86223 001 JAN 07, 1988
AB		20MG	N89367 001 APR 07, 1988
AB	DANBURY PHARMA	5MG	N86034 001 JAN 06, 1988
AB		10MG	N86032 001 JAN 07, 1988
AB	PAR PHARM	30MG	N87946 001 JAN 12, 1988

TABLET; SUBLINGUAL

> ADD >	<u>ISORDIL</u>		
> ADD >	AB	MYETH-AYERST	2.5MG
> ADD >	AB		5MG
> ADD >	AB		10MG
> ADD >			
> ADD >	AB	BARR LABS	10MG
> ADD >	AB	CORD LABS	2.5MG
> ADD >	AB		5MG
> ADD >	AB	DANBURY PHARMA	2.5MG
> ADD >	AB		5MG

ISOSORBIDE DINITRATE

			N12940 004 JUL 29, 1988
			N12940 003 JUL 29, 1988
			N12940 005 JUL 29, 1988
			N87545 001 SEP 18, 1986
			N86225 001 FEB 19, 1988
			N86222 001 FEB 19, 1988
			N86033 001 FEB 26, 1988
			N86031 001 SEP 29, 1987

ISOSORBIDE DINITRATE

TABLET, CONTROLLED RELEASE; ORAL

> ADD > ISORDIL
 > ADD > MYETH-AVERST 40MG N12882 001
 > ADD > JUL 29, 1988

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

AP PARKE DAVIS EQ 10MG BASE/ML N16812 001
 AP EQ 50MG BASE/ML N16812 002
 AP EQ 100MG BASE/ML N16812 003

KETAMINE HCL

AP QUAD PHARMS EQ 10MG BASE/ML N71949 001
 APR 11, 1988
 AP EQ 50MG BASE/ML N71950 001
 APR 11, 1988
 AP EQ 100MG BASE/ML N71951 001
 APR 11, 1988

LACTULOSE

SYRUP; ORAL

CHRONULAC

> ADD > AA MERRELL DOW 10GM/15ML N17884 001
 > ADD > CONSTILAC
 > ADD > AA ALRA LABS 10GM/15ML N71054 001
 > ADD > JUL 26, 1988

> DLT > /CEPHULAC/
 > DLT > /AA/ /MERRELL/DOW/ /10GM/15ML/ /N17884/001/
 > DLT > /LACTULOSE/
 > DLT > /AA/ /ROXANE/LABS/ /10GM/15ML/ /N17906/001/

> ADD > SYRUP; ORAL, RECTAL

CEPHULAC

> ADD > AA MERRELL DOW 10GM/15ML N17657 001
 > ADD > CHOLAC
 > ADD > AA ALRA LABS 10GM/15ML N71331 001
 > ADD > JUL 26, 1988
 > ADD > LACTULOSE
 > ADD > AA KALI DUPHAR 10GM/15ML N17906 001

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP BEN VENUE LABS EQ 100MG BASE/VIAL N89717 001
 MAR 28, 1988
 AP INTL PHARM EQ 3MG BASE/ML N89352 001
 JUN 01, 1988
 AP EQ 50MG BASE/VIAL N89353 001
 JUN 01, 1988
 AP LEDERLE LABS EQ 3MG BASE/ML N08107 001
 AP EQ 100MG BASE/VIAL N08107 004
 MAY 23, 1988
 AP QUAD PHARMS EQ 100MG BASE/VIAL N89636 001
 DEC 24, 1987

LEVODOPA

CAPSULE; ORAL

BENDOPA

/80/ /ICN/PHARMS/ /100MG/ /N16948/003/
 /80/ /250MG/ /N16948/001/
 /80/ /500MG/ /N16948/002/
 3 ICN PHARMS 100MG N16948 003
 3 250MG N16948 001
 3 500MG N16948 002

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ISOCAXINE HCL N/ LEVONORDEFIN

/AP/ /NOVOCOL/CHEN/ /0.05MG/ML; 2% /N84697/001/
 AP NOVOCOL PHARM 0.05MG/ML; 2% N84697 001
 AP POLOCAXINE N/ LEVONORDEFIN
 ASTRA PHARM PRODS 0.05MG/ML; 2% N89517 001
 APR 14, 1988

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

AP ABBOTT LABS 20% N89362 001
 MAY 25, 1988
 /AP/ /LEMMON/ /1% /N83627/001/
 /AP/ /2% /N83627/002/
 3 LEMMON 1% N83627 001
 3 2% N83627 002

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

<u>AB</u>	<u>LINCOCIN</u> UPJOHN	<u>EQ 300MG BASE/ML</u>	N50317 001
<u>AB</u>	<u>LINCOMYCIN HCL</u> QUAD PHARMS	<u>EQ 300MG BASE/ML</u>	N62784 001 MAR 14, 1988

LISINAPRIL

TABLET; ORAL

<u>AB</u>	<u>PRINIVIL</u> MS&D RES LABS	<u>5MG</u>	N19558 001 DEC 29, 1987
<u>AB</u>		<u>10MG</u>	N19558 002 DEC 29, 1987
<u>AB</u>		<u>20MG</u>	N19558 003 DEC 29, 1987
<u>AB</u>	<u>ZESTRIL</u> IMPERIAL CHEM	<u>5MG</u>	N19777 001 MAY 19, 1988
<u>AB</u>		<u>10MG</u>	N19777 002 MAY 19, 1988
<u>AB</u>		<u>20MG</u>	N19777 003 MAY 19, 1988

LOPERAMIDE HYDROCHLORIDESOLUTION; ORAL
IMODIUM

	<u>/JANSSEN/PHARMA/</u>	<u>/1MG/5ML/</u>	<u>/N19037/001/</u>
			<u>/JUL/31/1988/</u>
	o JANSSEN PHARMA	1MG/5ML	N19037 001 JUL 31, 1988

LORAZEPAM

TABLET; ORAL

<u>AB</u>	<u>LORAZEPAM</u> CORD LABS	<u>0.5MG</u>	N71193 001 APR 15, 1988
<u>AB</u>		<u>1MG</u>	N71194 001 APR 15, 1988
<u>AB</u>		<u>2MG</u>	N71195 001 APR 15, 1988
<u>AB</u>	WARNER CHILCOTT	<u>1MG</u>	N71038 001 JAN 12, 1988
<u>AB</u>		<u>2MG</u>	N71039 001 JAN 12, 1988

LOXAPINE SUCCINATE

CAPSULE; ORAL

<u>AB</u>	<u>LOXAPINE SUCCINATE</u> WATSON LABS	<u>EQ 5MG BASE</u>	N72204 001 JUN 15, 1988
<u>AB</u>		<u>EQ 10MG BASE</u>	N72205 001 JUN 15, 1988
<u>AB</u>		<u>EQ 25MG BASE</u>	N72206 001 JUN 15, 1988
<u>AB</u>		<u>EQ 50MG BASE</u>	N72062 001 JUN 15, 1988
<u>AB</u>	<u>LOXITANE</u> LEDERLE LABS	<u>EQ 5MG BASE</u>	N17525 001
<u>AB</u>		<u>EQ 10MG BASE</u>	N17525 002
<u>AB</u>		<u>EQ 25MG BASE</u>	N17525 003
<u>AB</u>		<u>EQ 50MG BASE</u>	N17525 004

MAPROTIline HYDROCHLORIDE

TABLET; ORAL

<u>AB</u>	<u>MAPROTIline HCL</u> AM THERPTCS	<u>25MG</u>	N72129 001 JAN 14, 1988
<u>AB</u>		<u>50MG</u>	N72130 001 JAN 14, 1988
<u>AB</u>		<u>75MG</u>	N72131 001 JAN 14, 1988
<u>AB</u>	WATSON LABS	<u>25MG</u>	N72162 001 JUN 01, 1988
<u>AB</u>		<u>50MG</u>	N72163 001 JUN 01, 1988
<u>AB</u>		<u>75MG</u>	N72164 001 JUN 01, 1988

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

<u>AA</u>	<u>ANTIEMET</u> ROERIG	<u>50MG</u>	N10721 001 JAN 20, 1982
<u>AA</u>	<u>MECLIZINE HCL</u> PAR PHARM	<u>50MG</u>	N89674 001 MAR 31, 1988

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

AB	PAR PHARM	EQ 50MG BASEM	N72077 001 MAR 10, 1988
AB		EQ 100MG BASEM	N72078 001 MAR 10, 1988
AB	PHARM BASICS	EQ 50MG BASEM	N71007 001 MAR 25, 1988
AB		EQ 100MG BASEM	N71008 001 MAR 25, 1988
AB	VITARINE	EQ 50MG BASEM	N71710 001 JUN 15, 1988
AB		EQ 100MG BASEM	N71684 001 JUN 15, 1988

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	VITARINE	250MG	N72179 001 APR 21, 1988
AB	PONSTEL PARKE DAVIS PR	250MG	N15034 003

MEPIVACaine HYDROCHLORIDE

INJECTABLE; INJECTION

ISOCATINE HCL

AB	NOVOCOL/CHEN	1/2/	N80925 001
AP	NOVOCOL PHARM	3/	

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AB	MALLARD	400MG	N15072 002
AB	PHARM BASICS	400MG	N87825 001
AB		400MG	N87826 001
AB	PHARM BASICS	200MG	N87825 001
AB		400MG	N87826 001

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/50M-21

AB	SEARLE PHARMS	0.05MG;1MG	N71539 001 APR 12, 1988
AB	WATSON LABS	0.05MG;1MG	N70758 001 JUL 01, 1988

TABLET; ORAL-28

NORETHIN 1/50M-28

AB	SEARLE PHARMS	0.05MG;1MG	N71540 001 APR 12, 1988
AB	WATSON LABS	0.05MG;1MG	N70759 001 JUL 01, 1988

MESTRANOL; NORETHYNODREL

TABLET; ORAL-20

ENOVID

AB	SEARLE	0.075MG;5MG	N10976 004
AB	SEARLE	0.1MG;2.5MG	N10976 006

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

AB	BOEHR INGEL	0.4%	N18761 002 OCT 10, 1986
----	-------------	------	----------------------------

METAPROTERENOL SULFATE

AB	ARMOUR PHARM	0.4%	N71275 001 JUL 27, 1988
AB	MY K LABS	5%	N71018 001 JUL 27, 1988
AB	PACO RES	0.4%	N72190 001 JUN 07, 1988
AB		0.6%	N71855 001 JUL 14, 1988
AB		0.6%	N71726 001 JUL 14, 1988

TABLET; ORAL

ALUPENT

AB	BOEHR INGEL	10MG	N15874 002
AB		20MG	N15874 001

METAPROTERENOL SULFATE

<u>TABLET; ORAL</u>		
<u>METAPROTERENOL SULFATE</u>		
AB	AM THERPTCS	10MG
		N72054 001
		JUN 23, 1988
AB		20MG
		N72055 001
		JUN 23, 1988
AB	PAR PHARM	10MG
		N72024 001
		JUN 28, 1988
AB		20MG
		N72025 001
		JUN 28, 1988
AB	PHARM BASICS	10MG
		N71013 001
		JAN 25, 1988
AB		20MG
		N71014 001
		JAN 25, 1988

METHOCARBAMOL

<u>TABLET; ORAL</u>		
<u>METHOCARBAMOL</u>		
/66/	/BARR LABS/	/500MG/
	2 BARR LABS	500MG
		N84488 001/
		N84488 001

METHOTREXATE SODIUM

<u>INJECTABLE; INJECTION</u>		
<u>METHOTREXATE</u>		
	LEDERLE LABS	EQ 1GM BASE/VIAL
		N11719 009
		APR 07, 1988
<u>METHOTREXATE SODIUM</u>		
> ADD > AP	PHARMACHEMIE	EQ 25MG BASE/ML
> ADD >		N89158 001
		JUL 08, 1988

METHOXSALEN

<u>CAPSULE; ORAL</u>		
<u>/OXSORALEN/</u>		
/BP/	/ELDER PHARMS/	/10MG/
	8-MOP	
	ELDER PHARMS	10MG
		N09048 001

METHYLDOPA

<u>TABLET; ORAL</u>		
<u>METHYLDOPA</u>		
AB	CORD LABS	125MG
		N71700 001
		MAR 02, 1988

METHYLDOPA

<u>TABLET; ORAL</u>		
<u>METHYLDOPA</u>		
AB	HALSEY DRUG	125MG
		N71751 001
		MAR 28, 1988
AB		250MG
		N71752 001
		MAR 28, 1988
AB		500MG
		N71753 001
		MAR 28, 1988
> ADD > AB	SIDMAK LABS	125MG
> ADD >		N72126 001
> ADD > AB		JUL 07, 1988
> ADD >		N72127 001
> ADD > AB		JUL 07, 1988
> ADD >		N72128 001
> ADD >		JUL 07, 1988

METHYLPHENIDATE HYDROCHLORIDE

<u>TABLET, CONTROLLED RELEASE; ORAL</u>		
<u>METHYLPHENIDATE HCL</u>		
AB	MD PHARM	20MG
		N89601 001
		JUN 01, 1988
<u>RETALIN-SR</u>		
AB	CIBA PHARM	20MG
		N18029 001
		MAR 30, 1982

METHYLPREDNISOLONE

<u>TABLET; ORAL</u>		
<u>MEDROL</u>		
AB	UPJOHN	24MG
AB		32MG
		N11153 005
		N11153 006
<u>METHYLPREDNISOLONE</u>		
AB	PAR PHARM	16MG
		N89207 001
		APR 25, 1988
AB		24MG
		N89208 001
		APR 25, 1988
AB		32MG
		N89209 001
		APR 25, 1988

METOCLOPRAMIDE HYDROCHLORIDE

<u>TABLET; ORAL</u>		
<u>CLOPRA</u>		
AB	QUANTUM PHARMS	EQ 5MG BASE
		N72384 001
		JUN 02, 1988
<u>METOCLOPRAMIDE HCL</u>		
AB	SIDMAK LABS	EQ 10MG BASE
		N71250 001
		FEB 03, 1988

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
REGLAN
 AB ROBINS EQ 5MG BASE N17854 002
 MAY 05, 1987

METOCURINE IODIDE

INJECTABLE; INJECTION
METOCURINE IODIDE
 AP QUAD PHARMS 2MG/ML N89443 001
 JUN 01, 1988

METURINE IODIDE
 AP LILLY 2MG/ML N06632 003

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION
 MEZLIN
 MILES PHARM EQ 20GM BASE/VIALM N50549 005
 MAR 02, 1988

EQ 20GM BASE/VIALM N62372 004
 MAR 02, 1988

MINOXIDIL

TABLET; ORAL
MINODYL
 > ADD > AB QUANTUM PHARMCS 2.5MG N72153 001
 > ADD > JUL 13, 1988

MITOMYCIN

INJECTABLE; INJECTION
 MITAMYCIN
 BRISTOL MYERS 40MG/VIALM N62336 003
 MAR 10, 1988

MORPHINE SULFATE

INJECTABLE; INJECTION
MORPHINE SULFATE
 AP ABBOTT LABS 0.5MG/ML N71849 001
 MAY 11, 1988

1MG/ML N71850 001
 MAY 11, 1988

MORPHINE SULFATE

TABLET, CONTROLLED RELEASE; ORAL
 MS CONTIN
 PURDUE FRDRK 60MG N19516 002
 APR 08, 1988

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
 NAFTIN
 HERBERT LABS 1% N19599 001
 FEB 29, 1988

NALIDIXIC ACID

TABLET; ORAL
NALIDIXIC ACID
 AB DANBURY PHARMA 250MG N71936 001
 JUN 29, 1988 : JUN 28, 1988

500MG N72061 001
 JUN 29, 1988 : JUN 28, 1988

1GM N71919 001
 JUN 29, 1988 : JUN 28, 1988

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL
 AP ELKINS SINN 0.02MG/ML N71272 001
 MAY 24, 1988

1MG/ML N71273 001
 MAY 24, 1988

1MG/ML N71274 001
 MAY 24, 1988

1MG/ML N71287 001
 MAY 24, 1988

1MG/ML N72076 001
 MAY 24, 1988

1MG/ML N72115 001
 APR 27, 1988

0.4MG/ML N71811 001
 JUL 19, 1988

> ADD > AP MARSAM PHARMS 0.4MG/ML N71083 001
 > ADD > JUL 28, 1988

> ADD > AP MARCAN 0.4MG/ML N71084 001
 > ADD > DUPONT CRI CARE 1MG/ML JUL 28, 1988

> ADD > AP 1MG/ML N71311 001
 > ADD > JUL 28, 1988

NITROFURANTOIN

TABLET; ORAL

<u>AB</u>	<u>NITROFURANTOIN</u>	<u>100MG</u>	<u>N80447/002</u>
<u>AB</u>	<u>BOLAR PHARM</u>	<u>100MG</u>	<u>N80447 002</u>

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

<u>AB</u>	<u>MACRODANTIN</u>	<u>50MG</u>	<u>N16620 001</u>
<u>AB</u>	<u>NORMICH EATON</u>	<u>100MG</u>	<u>N16620 002</u>
<u>AB</u>	<u>NITROFURANTOIN MACROCRYSTALLINE</u>	<u>50MG</u>	<u>N70248 001</u>
<u>AB</u>	<u>BOLAR PHARM</u>	<u>50MG</u>	<u>JUN 24, 1988</u>
<u>AB</u>		<u>100MG</u>	<u>N70249 001</u>
			<u>JUN 24, 1988</u>

NITROGLYCERIN

INJECTABLE; INJECTION

<u>AP</u>	<u>NITROGLYCERIN</u>	<u>5MG/ML</u>	<u>N71492 001</u>
<u>AP</u>	<u>LUITPOLD PHARMS</u>	<u>5MG/ML</u>	<u>MAY 24, 1988</u>
<u>AP</u>		<u>5MG/ML</u>	<u>N72034 001</u>
			<u>MAY 24, 1988</u>

> <u>ADD</u> >	<u>OINTMENT; TOPICAL</u>		
> <u>ADD</u> >	<u>NITROGLYCERIN</u>		
> <u>ADD</u> >	<u>ALTANA</u>	<u>2%</u>	<u>N87355 001</u>
> <u>ADD</u> >			<u>JUL 08, 1988</u>

NIZATIDINE

CAPSULE; ORAL

<u>AXID</u>			
<u>LILLY</u>	<u>150MG</u>	<u>N19508 001</u>	
		<u>APR 12, 1988</u>	
	<u>300MG</u>	<u>N19508 002</u>	
		<u>APR 12, 1988</u>	

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

<u>BD</u>	<u>AVENTYL HCL</u>	<u>EQ 10MG BASE</u>	<u>N14684 001</u>
<u>BD</u>	<u>LILLY</u>	<u>EQ 25MG BASE</u>	<u>N14684 002</u>
<u>BP</u>		<u>EQ 10MG BASE</u>	<u>N14684 001</u>
<u>BP</u>		<u>EQ 25MG BASE</u>	<u>N14684 002</u>
<u>BD</u>	<u>PAMELOR</u>	<u>EQ 10MG BASE</u>	<u>N18013 001</u>
<u>BD</u>	<u>SANDOZ PHARMS</u>	<u>EQ 25MG BASE</u>	<u>N18013 002</u>
<u>BP</u>		<u>EQ 10MG BASE</u>	<u>N18013 001</u>
<u>BP</u>		<u>EQ 25MG BASE</u>	<u>N18013 002</u>

NYSTATIN

CREAM; TOPICAL

<u>AT</u>	<u>NYSTATIN</u>	<u>100,000 UNITS/GM</u>	<u>N62949 001</u>
	<u>NASKA PHARMA</u>		<u>JUN 13, 1988</u>

SUSPENSION; ORAL

<u>AA</u>	<u>NYSTATIN</u>	<u>100,000 UNITS/ML</u>	<u>N62876 001</u>
	<u>THAMES PHARMA</u>		<u>FEB 29, 1988</u>

OXAZEPAM

CAPSULE; ORAL

<u>AB</u>	<u>OXAZEPAM</u>	<u>10MG</u>	<u>N71955 001</u>
<u>AB</u>	<u>AM THERPTCS</u>	<u>15MG</u>	<u>MAR 03, 1988</u>
<u>AB</u>		<u>30MG</u>	<u>N71956 001</u>
<u>AB</u>		<u>30MG</u>	<u>MAR 03, 1988</u>
<u>AB</u>	<u>CHELSEA LABS</u>	<u>10MG</u>	<u>N71957 001</u>
<u>AB</u>		<u>15MG</u>	<u>MAR 03, 1988</u>
<u>AB</u>		<u>30MG</u>	<u>N71661 001</u>
<u>AB</u>		<u>15MG</u>	<u>MAR 02, 1988</u>
<u>AB</u>		<u>30MG</u>	<u>N71662 001</u>
<u>AB</u>	<u>CORD LABS</u>	<u>10MG</u>	<u>MAR 02, 1988</u>
<u>AB</u>		<u>15MG</u>	<u>N71813 001</u>
<u>AB</u>		<u>30MG</u>	<u>APR 19, 1988</u>
			<u>N71756 001</u>
			<u>APR 19, 1988</u>
			<u>N71814 001</u>
			<u>APR 19, 1988</u>

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / JAN'88 - JUL'88

33

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

/BP/ /MYLAN/PHARMS/ /10MG/

/BP/ /15MG/

/BP/ /30MG/

3 MYLAN PHARMS 10MG

3 15MG

3 30MG

AB PUREPAC PHARM 10MG

AB 15MG

AB 30MG

> ADD > AB ZENITH LABS 10MG

> ADD > 15MG

> ADD > AB 30MG

> ADD > AB 30MG

> ADD > 30MG

> DLT > /BP/ /10MG/

> DLT > /BP/ /15MG/

> DLT > /BP/ /30MG/

> DLT > /BP/ /30MG/

> DLT > /BP/ /30MG/

SERAX

AB NYETH 10MG

AB 15MG

AB 30MG

/BP/ /10MG/

/BP/ /15MG/

/BP/ /30MG/

ZANOPAM

AB QUANTUM PHARMS 10MG

AB 15MG

AB 30MG

/N71713/001/

/OCT/20./1987/

/N71714/001/

/OCT/20./1987/

/N71715/001/

/OCT/20./1987/

N71713 001

OCT 20, 1987

N71714 001

OCT 20, 1987

N71715 001

OCT 20, 1987

N72251 001

APR 14, 1988

N72252 001

APR 14, 1988

N72253 001

APR 14, 1988

N70943 001

AUG 03, 1987

N70944 001

AUG 03, 1987

N70945 001

AUG 03, 1987

/N70943/001/

/AUG/03./1987/

/N70944/001/

/AUG/03./1987/

/N70945/001/

/AUG/03./1987/

/N70943/001/

/AUG/03./1987/

/N70944/001/

/AUG/03./1987/

/N70945/001/

/AUG/03./1987/

N70650 001

MAR 01, 1988

N70640 001

MAR 01, 1988

N70641 001

MAR 01, 1988

OXYBUTYRIN CHLORIDE

TABLET; ORAL

EXTROPAN

AB MARION LABS 5MG

N17577 001

OXYBUTYRIN CHLORIDE

AB PHARM BASICS 5MG

N70746 001

MAR 10, 1988

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

OXYTETRACYCLINE HCL

/AB/ /PUREPAC/PHARM/ /EQ 250MG BASE/

3 PUREPAC PHARM

EQ 250MG BASE

/N60634/001/

N60634 001

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM

AP ELKINS SINN 1MG/ML

N72058 001

MAR 23, 1988

AP 2MG/ML

N72059 001

MAR 23, 1988

AP 2MG/ML

N72060 001

MAR 23, 1988

PANCURONIUM BROMIDE

AP ASTRA PHARM PRODS 1MG/ML

N72210 001

MAR 31, 1988

AP 2MG/ML

N72211 001

MAR 31, 1988

AP 2MG/ML

N72212 001

MAR 31, 1988

AP 2MG/ML

N72213 001

MAR 31, 1988

AP QUAD PHARMS 1MG/ML

N72209 001

JUN 03, 1988

AP 2MG/ML

N72208 001

JUN 03, 1988

PAVULON

AP ORGANON 1MG/ML

N17015 002

AP 2MG/ML

N17015 001

PARAMETHADIONE

> DLT > /CONCENTRATE//ORAL/

> DLT > /PARADIONE/

> DLT > /AB/ /ABBOTT/LABS/ /300MG/ML/

/N66888/002/

PARAMETHADIONE

> ADD > SOLUTION; ORAL
 > ADD > PARADIONE
 > ADD > AA ABBOTT LABS 300MG/ML N06800 002

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

PENICILLIN G POTASSIUM
 /66/ /PUREPAC/PHARM/ /400,000 UNITS/5ML/ /N61740/002/
 @ PUREPAC PHARM 400,000 UNITS/5ML N61740 002

TABLET; ORAL

PENICILLIN G POTASSIUM
 /66/ /PUREPAC/PHARM/ /250,000 UNITS/ /N61588/002/
 /66/ /PUREPAC/PHARM/ /400,000 UNITS/ /N61588/003/
 @ PUREPAC PHARM 250,000 UNITS N61588 002
 @ 400,000 UNITS N61588 003

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

PENICILLIN V POTASSIUM
 /66/ /PUREPAC/PHARM/ /EQ 250MG BASE/5ML/ /N61758/002/
 @ PUREPAC PHARM EQ 250MG BASE/5ML N61758 002

TABLET; ORAL

PENICILLIN V POTASSIUM
 /66/ /PUREPAC/PHARM/ /EQ 250MG BASE/ /N61571/002/
 /66/ /PUREPAC/PHARM/ /EQ 500MG BASE/ /N61571/003/
 @ PUREPAC PHARM EQ 250MG BASE N61571 002
 @ EQ 500MG BASE N61571 003

PERPHENAZINE

SYRUP; ORAL

TRILAFON
 /SCHERING/ /2MG/5ML/ /N11294/002/
 @ SCHERING 2MG/5ML N11294 002

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE
 /66/ /BARR/LABS/ /35MG/ /N83644/001/
 /66/ /BARR/LABS/ /35MG/ /N83684/001/
 /66/ /BARR/LABS/ /35MG/ /N83686/001/
 /66/ /BARR/LABS/ /35MG/ /N83687/001/
 /66/ /BARR/LABS/ /35MG/ /N84831/001/
 /66/ /BARR/LABS/ /35MG/ /N84834/001/
 /66/ /BARR/LABS/ /35MG/ /N84835/001/
 @ BARR LABS 35MG N83644 001
 @ 35MG N83684 001
 @ 35MG N83686 001
 @ 35MG N83687 001
 @ 35MG N84831 001
 @ 35MG N84834 001
 @ 35MG N84835 001

PHENTERMINE RESIN COMPLEX

CAPSULE, CONTROLLED RELEASE; ORAL

IONAMIN-30
 AB PENNALT EQ 30MG BASE N11613 002
PHENTERMINE RESIN 30
 AB QUANTUM PHARMS EQ 30MG BASE N89120 001
 FEB 04, 1988

PIPERACETAZINE

TABLET; ORAL

GUIDE
 /DOW/PHARMS/ /10MG/ /N13615/001/
 DOW PHARMS 10MG N13615 001
 /25MG/ /N13615/002/
 25MG N13615 002

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

COLONLITE
 AA DYNAPHARM 227.1GM/PACKET; 2.82GM/PACKET;
 6.36GM/PACKET; 5.53GM/PACKET;
 21.5GM/PACKET N71320 001
 APR 20, 1988

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

PONDER FOR RECONSTITUTION; ORAL

COLYTE
AB REED & CARNICK 227.1GM/PACKET; 2.82GM/PACKET;
6.36GM/PACKET; 5.53GM/PACKET;
21.5GM/PACKET N18983 004
 OCT 26, 1984

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

OCL
1.5/ABBOTT/LABS/ 1.6GM/100ML; 75MG/100ML; 168MG/100ML;
1.46MG/100ML; 1.29GM/100ML; 1.46MG/100ML;
1.29GM/100ML; 1.46MG/100ML; 1.29GM/100ML;
ABBOTT LABS 6GM/100ML; 75MG/100ML; 168MG/100ML;
 146MG/100ML;
 1.29GM/100ML N19284 001
 APR 30, 1986

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE
AP STERIS LABS 2MEQ/MLM N89163 001
 MAR 10, 1988

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE
1BX/ BARR LABS/ 5MG/ 1.46MG/100ML;
BARR LABS 5MG N84426 002

PREDNISONE

TABLET; ORAL

PREDNISONE
AB SUPERPHARM 5MG N88865 001
 OCT 25, 1984
AB 10MG N88866 001
 OCT 25, 1984
AB 20MG N88867 001
 OCT 25, 1984
1BX/ 5MG/ 1.46MG/100ML;
1BX/ 10MG/ 1.46MG/100ML;
1BX/ 20MG/ 1.46MG/100ML;

PROBUCOL

TABLET; ORAL

LORELCO
MERRELL DOW 500MG N17535 002
 JUL 06, 1988

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL
AP WARNER CHILCOTT 100MG/MLM N89528 001
 MAY 03, 1988
AP 500MG/MLM N89529 001
 MAY 03, 1988

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE
AP ELKINS SINN EQ 5MG BASE/MLM N89523 001
 MAY 03, 1988
AP QUAD PHARMS EQ 5MG BASE/MLM N89637 001
 FEB 01, 1988
AP EQ 5MG BASE/MLM N89638 001
 FEB 01, 1988
AP STERLING DRUG EQ 5MG BASE/MLM N89703 001
 APR 07, 1988

PROMETHAZINE HYDROCHLORIDEINJECTABLE; INJECTION

PROMETHAZINE HCL
MARSAM PHARMS 25MG/ML
 AP
50MG/ML
 AP

N89463 001
 MAY 02, 1988
 N89477 001
 MAY 02, 1988

> DLT > AB
 > DLT >
 > ADD >
 > ADD >

PROPRANOLOL HYDROCHLORIDETABLET; ORALPROPRANOLOL HCL

/AB/ /LEMON/ /10MG/
 & LEMMON 10MG
/AB/ /PARKE/DAVIS/ /10MG/

AB SIDMAK LABS 10MG
AB 20MG
AB 40MG
AB 60MG

AB 80MG
AB 90MG

AB SUPERPHARM 10MG

AB 20MG

AB 40MG

AB 80MG

AB WARNER CHILCOTT 10MG

> ADD > AB ZENITH LABS 10MG

> ADD > AB 20MG

> ADD > AB 40MG

> ADD > AB 60MG

> ADD > AB 80MG

> ADD >

TABLET; ORAL

PROMETHAZINE HCL
/BP/ /BARR/LABS/ /12.5MG/
/BP/ /BARR/LABS/ /25MG/
/BP/ /BARR/LABS/ /50MG/
 & BARR LABS 12.5MG
 & 25MG
 & 50MG

/N84555/001/
/N84554/001/
/N84557/001/
 N84555 001
 N84554 001
 N84557 001

PROPOXYPHENE HYDROCHLORIDECAPSULE; ORAL

PROPOXYPHENE HCL
/AB/ /BANMAX/PHARMS/ /65MG/
 & BANMAX PHARMS 65MG
/AB/ /BARR/LABS/ /65MG/
 & BARR LABS 65MG

/N83184/001/
 N83184 001
/N83186/001/
 N83186 001

PROPRANOLOL HYDROCHLORIDETABLET; ORALPROPRANOLOL HCL

> ADD > AB INVAMED 10MG
 > ADD > AB 20MG
 > ADD > AB 40MG
 > ADD > AB 60MG
 > ADD > AB 80MG
 > ADD > AB 90MG
 > ADD > AB 10MG
 > ADD > AB 20MG
 > ADD > AB 40MG
 > ADD > AB 80MG

N71658 001
 JUL 05, 1988
 N71687 001
 JUL 05, 1988
 N71688 001
 JUL 05, 1988
 N72197 001
 JUL 05, 1988
 N71689 001
 JUL 05, 1988
 N72198 001
 JUL 05, 1988
 N72117 001
 JUN 23, 1988
 N72118 001
 JUN 23, 1988
 N72119 001
 JUN 23, 1988
 N72120 001
 JUN 23, 1988

/N70232/001/
/OCT/07/1987/
 N70232 001
 OCT 07, 1987
/N70438/001/
/SEP/15/1986/
 N71972 001
 APR 06, 1988
 N71973 001
 APR 06, 1988
 N71974 001
 APR 06, 1988
 N71975 001
 APR 06, 1988
 N71976 001
 APR 06, 1988
 N71977 001
 APR 06, 1988
 N71515 001
 JUN 08, 1988
 N71516 001
 JUN 08, 1988
 N71517 001
 JUN 08, 1988
 N71518 001
 JUN 08, 1988
 N70438 001
 SEP 15, 1986
 N72063 001
 JUL 29, 1988
 N72066 001
 JUL 29, 1988
 N72067 001
 JUL 29, 1988
 N72068 001
 JUL 29, 1988
 N72069 001
 JUL 29, 1988

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

/AP/	/UPJOHN/	/50MG/VIAL/	/N07413/001/
/AP/		/250MG/VIAL/	/N07413/002/
			/AUG 02, 1984/
	3 UPJOHN	50MG/VIAL	N07413 001
	3	250MG/VIAL	N07413 002
			AUG 02, 1984

GUINESTROL

TABLET; ORAL

ESTROVIS

/PARKE/DAVIS/

3 PARKE DAVIS

3

/0.1MG/	/N16768/002/
0.1MG	N16768 002
/0.2MG/	/N16768/003/
0.2MG	N16768 003

RAUMOLFIA SERPENTINA

TABLET; ORAL

RAUVAL

/3/VALE/CHEM/

/3/

BP	VALE CHEM	/50MG/	/N09108/002/
BP		/100MG/	/N09108/004/
		50MG	N09108 002
		100MG	N09108 004

RESERPINE

TABLET; ORAL

RESERPINE

/BARR/LABS/

3 BARR LABS

/0.25MG/	/N80721/002/
0.25MG	N80721 002

SECOBARBITAL SODIUM

CAPSULE; ORAL

SODIUM SECOBARBITAL

/AB/	/BARR/LABS/	/100MG/	/N84225/001/
	3 BARR LABS	100MG	N84225 001

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	900MG/100MLM	N19635 002
			MAR 09, 1988

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT LABS	450MG/100MLM	N19759 001
			JUN 08, 1988
AP	KENDALL MCGAW	450MG/100MLM	N19635 001
			MAR 09, 1988

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	3GM/100MLM	N19635 003
			MAR 09, 1988
AP	TRAVENOL LABS	3GM/100ML	N19022 001
			NOV 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100MLM	N19635 004
			MAR 09, 1988
AP	TRAVENOL LABS	5GM/100ML	N19022 002
			NOV 01, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

/ELKINS/SINN/

3 ELKINS SINN

/30%/	/N80516/001/
30%	N80516 001

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

/AB/	/BARR/LABS/	/500MG/	/N87189/001/
	3 BARR LABS	500MG	N87189 001

/JUL 25, 1983/
JUL 25, 1983

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

TRIMETH/SULFA

AB	NASKA PHARMA	200MG/5ML; 40MG/5MLM	N72289 001
			MAY 23, 1988
AB		200MG/5ML; 40MG/5MLM	N72398 001
			MAY 23, 1988
AB		200MG/5ML; 40MG/5MLM	N72399 001
			MAY 23, 1988

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE
/AB/ /BARR LABS/
3 BARR LABS

500MG
500MG

/N84031/001/
N84031 001

SULINDAC

TABLET; ORAL

CLINORIL
AB MS&D
AB

150MG
200MG

N17911 001
N17911 002

SULINDAC
AB AM THERPTCS

150MG

N72171 001
MAY 23, 1988

AB 200MG

N72172 001
MAY 23, 1988

AB DANBURY PHARMA 150MG

APR 03, 1990 : MAR 03, 1988

AB 200MG

N71891 001
N71795 001
APR 03, 1990 : MAR 03, 1988

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM
AB CORD LABS

15MG

N71427 001
JAN 12, 1988

AB 30MG

N71428 001
JAN 12, 1988

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

HYTRIN
> DLT > /2/ /ABBOTT LABS/
> DLT > /10MG/
> ADD > ABBOTT LABS
> ADD > 10MG

10MG

/N19057/004/
/AUG/07/1987/
N19057 004
AUG 07, 1987

TERCONAZOLE

SUPPOSITORY; VAGINAL

TERAZOL 3
ORTHO PHARM

80MG

N19641 001
MAY 24, 1988

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HCL
AB VITARINE

250MG

N61471 001

THEOPHYLLINE

ELIXIR; ORAL

THEOPHYLLINE
AA NASKA PHARMA

80MG/15ML

N89223 001
MAY 27, 1988

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
AP TRAVENOL LABS

320MG/100ML

N18649 006
NOV 13, 1985

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ABBOTT LABS

320MG/100ML

N19211 006
JAN 20, 1988

TABLET, CONTROLLED RELEASE; ORAL

THEOLAIR-SR
BC RIKER LABS

250MG

N86363 002
JUL 16, 1987

/250MG/

/N86363/002/
/JUL/16/1987/

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL
AB PAR PHARM

150MG

N89764 001
FEB 09, 1988

AB 200MG

N89765 001
FEB 09, 1988

AB ROXANE LABS 25MG

N88664 001
MAR 15, 1984

TIOCONAZOLE

OINTMENT; VAGINAL

VAGISTAT
/ROERIG/

16.5%

/N19355/001/
/DEC/30/1986/

3 ROERIG

6.5%

N19355 001
DEC 30, 1986

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE
 AB PHARM BASICS 100MG N71355 001
 JAN 11, 1988

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE
 /AB/ BANMAX PHARMS /500MG/ N86141/001/
 BANMAX PHARMS 500MG N86141 001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
DESYREL
 AB MEAD JOHNSON 150MG N18207 003
 MAR 25, 1985

TABLET; ORAL
TRAZODONE HCL
 AB PUREPAC PHARM 50MG N71636 001
 APR 18, 1988

AB 100MG N71514 001
 APR 18, 1988

TABLET; ORAL
TRAZON-150
 AB SIDMAK LABS 150MG N71525 001
 MAR 09, 1988

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE
 /BP/ BARR LABS /2MG/ N84286/001/
 /BP/ /2MG/ N84318/001/
 /BP/ /4MG/ N84267/001/
 /BP/ /4MG/ N84319/001/
 /BP/ /8MG/ N84268/001/
 /BP/ /8MG/ N84320/001/
 BARR LABS 2MG N84286 001
 2MG N84318 001
 4MG N84267 001
 4MG N84319 001
 8MG N84268 001
 8MG N84320 001

TRIAZOLAM

TABLET; ORAL
 HALCION
 /UPJOHN/ /0.5MG/ N17892/002/
 NOV 15, 1982
 0.5MG N17892 002
 NOV 15, 1982

TRICLOFOS SODIUM

SOLUTION; ORAL
 TRICLOS
 /MERRELL/DOW/ /1.5GM/15ML/ N16830/001/
 > DLT > MERRELL DOW 1.5GM/15ML N16830 001
 > ADD >

TABLET; ORAL
 TRICLOS
 /MERRELL/DOW/ /750MG/ N16809/002/
 > DLT > MERRELL DOW 750MG N16809 002
 > ADD >

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION
 PATHILON
 /LEDERLE/LABS/ /10MG/ML/ N09729/001/
 10MG/ML N09729 001

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL
 AB BCLAR PHARM EQ 1MG BASE N85975 001
 JUN 23, 1988
 AB EQ 2MG BASE N85976 001
 JUN 23, 1988
 AB EQ 5MG BASE N85973 001
 JUN 23, 1988
 AB EQ 10MG BASE N88710 001
 JUN 23, 1988

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM
 AB BARR LABS 100MG
 /66/ /200MG/
 /3/ /100MG/
 2 200MG

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

TRIPLENNAMINE HCL
 /66/ /BARR LABS/ /50MG/
 2 BARR LABS 50MG

URSODIOL

CAPSULE; ORAL

ADD > ACTIGALL
ADD > 2 CIBA PHARM 150MG
ADD > 300MG
ADD >
 /DEURSIL/
 /SIPHARMEX/ /150MG/
 /300MG/

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LYPHOCIN
 AP LYPHOMED EQ 1GM BASE/VIAL
 AP EQ 5GM BASE/VIALM

N70494 001
 JAN 22, 1986
 /N70494/001/
 /MAR/14/1986/
 /N70494/001/
 /JAN/22/1986/
 N70495 001
 MAR 14, 1986

/N80744/001/
 N80744 001

N19594 001
 DEC 31, 1987
 N19594 002
 DEC 31, 1987

/N19594/001/
 /DEC/31/1987/
 /N19594/002/
 /DEC/31/1987/

N62667 002
 JUL 31, 1987
 N62663 003
 JUN 03, 1988

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOCTIN HCL

AP LILLY EQ 1GM BASE/VIAL N60180 002
 AP EQ 1GM BASE/VIAL MAR 21, 1986
 AP EQ 1GM BASE/VIAL N62476 002
 AP EQ 1GM BASE/VIAL MAR 21, 1986
 AP EQ 1GM BASE/VIAL N62716 002
 AP EQ 1GM BASE/VIAL MAR 13, 1987
 AP EQ 1GM BASE/VIAL N62812 002
 AP EQ 10GM BASE/VIAL NOV 17, 1987
 AP EQ 10GM BASE/VIAL N62812 003
 AP EQ 10GM BASE/VIAL NOV 17, 1987

VANCOLED

AP LEDERLE LABS EQ 1GM BASE/VIALM N62682 002
 AP EQ 5GM BASE/VIAL MAR 30, 1988
 AP EQ 10GM BASE/VIALM N62682 004
 AP EQ 2GM BASE/VIALM MAY 11, 1988
 EQ 10GM BASE/VIALM N62682 005
 EQ 2GM BASE/VIALM MAY 11, 1988
 EQ 500MG BASE/VIALM N62682 003
 EQ 1GM BASE/VIALM MAY 11, 1988

> ADD > VANCOMYCIN HCL
 > ADD > AP QUAD PHARMS EQ 500MG BASE/VIALM N62845 001
 > ADD > EQ 1GM BASE/VIALM JUL 15, 1988
 > ADD > N62845 002
 > ADD > JUL 15, 1988

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

CALAN
 /SEARLE/ /160MG/ /N18817/004/
 AB SEARLE PHARMS 40MG N18817 003
 2 160MG FEB 23, 1988
 N18817 004
 FEB 23, 1988
 N18593 003
 NOV 23, 1987
ISOPTEN
 AB KNOLL PHARM 40MG
 AB VERAPAMIL HCL 80MG
 AB CORD LABS 120MG
 AB 80MG
 AB LEDERLE LABS 120MG
 AB 120MG
 N71423 001
 MAY 24, 1988
 N71424 001
 MAY 25, 1988
 N71880 001
 APR 05, 1988
 N71881 001
 APR 05, 1988

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HCL

AB	MUTUAL PHARM	80MG M	N71488 001 JAN 13, 1988
AB		120MG M	N71489 001 JAN 13, 1988

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCOREX

> ADD >			
> ADD >	AP	BRISTOL LABS	5MG/VIAL M
> ADD >			N70867 001 JUL 12, 1988

VINCRIStINE SULFATE

AP	BULL LABS	1MG/VIAL M	N71559 001 APR 11, 1988
AP		2MG/VIAL M	N71560 001 APR 11, 1988
AP		5MG/VIAL M	N71561 001 APR 11, 1988
AP	QUAD PHARMS	1MG/VIAL	N71222 001 MAR 07, 1988
AP		2MG/VIAL	N71223 001 MAR 07, 1988
AP		5MG/VIAL	N71937 001 MAR 07, 1988

VINCRIStINE SULFATE PFS

AP	BULL LABS	1MG/ML M	N71484 001 APR 19, 1988
----	-----------	---------------------	----------------------------

WATER FOR INJECTION, STERILE

LIQUID; N/A

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	BAXTER	100 Z M	N18632 002 APR 19, 1988
AP	KENDALL MCGAW	100 Z M	N19633 001 FEB 29, 1988

XYLOSE

POWDER; ORAL

XYLOSE

/AA/	LYNE LABS/	/25GM/BOT/	/N18856/001/ MAR 26, 1987/
	Q LYNE LABS	25GM/BOT	N18856 001 MAR 26, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL

TYLENOL

MCNEIL CONSUMER

120MG

N17756 002

650MG

N17756 001

/MCNEIL/LABS/

/120MG/

/N17756/002/

/650MG/

/N17756/001/

DEXDROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, CONTROLLED RELEASE; ORAL

RESPORAL

PIONEER PHARMS

6MG;120MG

N89139 001

JUN 16, 1988

HYDROCORTISONE

OINTMENT; TOPICAL

HC (HYDROCORTISONE)

C&M PHARMA

0.5%

N80481 001

IBUPROFEN

TABLET; ORAL

IBUPROFEN

DANBURY PHARMA

200MG

N71905 001

MAR 08, 1988

INTERPHARM

200MG

N72199 001

MAY 23, 1988

INVAMED

200MG

N71807 001

FEB 25, 1988

MEDICOPHARMA

200MG

N71639 001

FEB 02, 1988

MYLAN PHARMS

200MG

N71870 001

MAY 05, 1988

> ADD >

PRIVATE FHLTNS

200MG

N72299 001

JUL 01, 1988

> ADD >

ZENITH LABS

200MG

N72040 001

APR 29, 1988

NUPRIN

BRISTOL MYERS

200MG

N72035 001

FEB 16, 1988

200MG

N72036 001

FEB 16, 1988

IBUPROFEN

TABLET; ORAL

NUPRIN

/UPJOHN/

/200MG/

/N19012/003/

/JUL/29/1987/

/200MG/

/N19012/001/

/MAY/18/1988/

a UPJOHN

200MG

N19012 001

MAY 18, 1984

a

200MG

N19012 003

JUL 29, 1987

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30

NORDISK USA

30 UNITS/ML;

70 UNITS/ML

N19585 001

MAR 11, 1988

INSULIN ZINC SUSP EXTENDED BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION

HUMULIN U

/LILLY/

/40 UNITS/ML/

/N19571/001/

/JUN/16/1987/

a LILLY

40 UNITS/ML

N19571 001

JUN 10, 1987

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM A-D

MCNEIL CONSUMER

1MG/5ML

N19487 001

MAR 01, 1988

NONOXYNOL-9

SPONGE; VAGINAL

TODAY

/WHI/

/1GM/

/N18683/001/

/APR/01/1983/

WHITEHALL LABS

1GM

N18683 001

APR 01, 1983

DRUG PRODUCTS IN THE DIVISION OF BLOOD AND BLOOD PRODUCTS / CUMULATIVE SUPPLEMENT NUMBER 7 / JAN '88 - JUL '88
APPROVED UNDER SECTION 505 OF THE ACT LIST

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

MACRODEX(R)

PHARMACIA INC

6GM/100ML;0.9GM/100ML

N 06826

ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG". SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

ORPHAN DRUG EXCLUSIVE APPROVAL STATUS (CODED ODE) APPLIES ONLY TO THE APPROVED OR LICENSED INDICATION(S) FOR WHICH ORPHAN DRUG DESIGNATION HAS BEEN GRANTED PURSUANT TO SECTION 526 OF THE ACT.

FOR THE FOLLOWING DRUG PRODUCTS WITH ORPHAN DRUG EXCLUSIVE APPROVAL STATUS, THE SPONSOR HAS SEVEN YEARS OF EXCLUSIVE APPROVAL FOR THE APPROVED INDICATION BEGINNING ON THE DATE OF NDA, ANTIBIOTIC APPLICATION, OR BIOLOGICAL LICENSE APPROVAL FOR THE DRUG. NO SUBSEQUENT SPONSOR MAY RECEIVE APPROVAL OF AN NDA, BIOLOGICAL LICENSE, PAPER NDA, ANTIBIOTIC APPLICATION, ANDA, OR ABBREVIATED ANTIBIOTIC APPLICATION DURING THE SEVEN YEAR PERIOD FOR THE DRUG AND INDICATION(S) FOR WHICH ODE STATUS IS MAINTAINED UNLESS THE EXCLUSIVE APPROVAL HAS BEEN REVOKED AS DESCRIBED ABOVE OR THE SUBSEQUENT SPONSOR HAS OBTAINED WRITTEN CONSENT FROM THE SPONSOR WHO HAS RECEIVED EXCLUSIVE APPROVAL.

BIOLOGICAL PRODUCTS, ANTIBIOTICS, AND DRUGS THAT HAVE BEEN APPROVED UNDER SECTION 505 OR 507 OF THE ACT OR UNDER SECTION 351 OF THE PUBLIC HEALTH SERVICE ACT FOR MARKETING AND HAVE BEEN GIVEN ORPHAN DRUG EXCLUSIVE APPROVAL WILL BE NOTED BY THE ABBREVIATION ODE IN THE PATENT AND EXCLUSIVITY INFORMATION ADDENDUM. DRUG PRODUCTS THAT HAVE RECEIVED THE WRITTEN PERMISSION OF THE SPONSOR THAT HAS ORPHAN DRUG EXCLUSIVE APPROVAL TO BE APPROVED UNDER SECTION 527(b)(2) OF THE ACT ARE ALSO NOTED BY THE ABBREVIATION ODE IN THE PATENT AND EXCLUSIVITY INFORMATION ADDENDUM. THESE DRUG PRODUCTS DO NOT HAVE ANY EXCLUSIVE APPROVAL RIGHTS OF THEIR OWN, BUT CAN BE MARKETING BECAUSE OF THE CONSENT GIVEN BY THE SPONSOR THAT HAS EXCLUSIVE APPROVAL. THESE PRODUCTS ARE MARKED BY AN (*) NEXT TO THE APPLICANT'S NAME.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL

DRUG PRODUCTS

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME DOSAGE FORM; ROUTE	APPLICANT	APPL. PROD. APPROVAL DATE	EXCLUSIVITY EXP. DATE
METHOTREXATE SODIUM EQ 1GM BASE/VIAL	METHOTREXATE SODIUM INJECTABLE; INJECTION	LEDERLE LABS	11719 009 APR 07, 1988	ODE APR 07, 1995

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 1988 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFN-250, ROOM 17B-06, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

NAME OF DRUG (DOSAGE FORM)	DATE	REVISED DATE
CARBAMAZEPINE (TABLET)	JAN 01, 1988	
CLINDAMYCIN (CAPSULE)	MAY 31, 1988	
CYCLOBENZAPRINE HYDROCHLORIDE (TABLET)	JAN 25, 1988	
DOXYCYCLINE HYCLATE (CAPSULE AND TABLET)	APR 11, 1988	
FENOPROFEN (CAPSULE AND TABLET)	AUG 27, 1987	
INDOMETHACIN (CAPSULE)	JAN 27, 1988	FEB 03, 1988
MESTRANOL; NORETHYNODREL (TABLET)	MAY 13, 1988	
METAPROTERENOL SULFATE (TABLET)	MAR 18, 1988	
NORETHINDRONE; ETHINYL ESTRADIOL (TABLET)	MAR 18, 1988	
PRAZEPAM (CAPSULE AND TABLET)	JUL 26, 1988	

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 5MG	87 P-0376/ CP0002	ANABOLIC	NEW STRENGTH	APPROVED FEB 12, 1988
ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	650MG 5MG	87 P-0376/CP	ANABOLIC	NEW STRENGTH	APPROVED FEB 12, 1988
CHLORZOXAZONE CAPSULE; ORAL	500MG	82 N-0032/ CP0006	MIKART	NEW DOSAGE FORM	APPROVED JAN 13, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CISPLATIN INJECTABLE; INJECTION	1MG/ML (10ML/VIAL) (50ML/VIAL) (100ML/VIAL)	87 P-0421/CP	BULL LABS	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 29, 1988
CISPLATIN INJECTABLE; INJECTION	1MG/ML (20ML/VIAL)	88 P-0010/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	APPROVED APR 01, 1988
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	20MG/ML (500ML/CONTAINER)	88 P-0011/CP	BAXTER HLTHCARE	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUN 10, 1988
FLUOROURACIL INJECTABLE; INJECTION	50MG/ML (5ML/VIAL)	88 P-0052/CP	BEN VENUE LABS	NEW STRENGTH	APPROVED MAR 21, 1988
HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE SOFT GELATIN CAPSULE; ORAL	1.5MG 5MG	88 P-0061/CP	KLEINFELD, KAPLAN AND BECKER	NEW DOSAGE FORM	APPROVED MAY 12, 1988
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML 40MG/5ML	87 P-0399/CP	BURDITT, BOWLES, RADZIUS AND RUBERRY	NEW DOSAGE FORM	APPROVED FEB 16, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML 80MG/5ML	87 P-0399/CP	BURDITT, BOWLES, RADZIUS AND RUBERRY	NEW DOSAGE FORM	APPROVED FEB 16, 1988
HYDROCHLOROTHIAZIDE; TRIAMTERENE TABLET; ORAL	25MG 50MG	87 P-0335/CP	PAR PHARM	NEW DOSAGE FORM	APPROVED FEB 26, 1988
LEUCOVORIN CALCIUM SOLUTION; ORAL	EQ 1MG BASE/ML	88 P-0149/CP	ROXANE LABS	NEW DOSAGE FORM	APPROVED JUL 25, 1988
MEPERIDINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (50ML/CONTAINER)	88 P-0008/CP	LYPHOMED	NEW STRENGTH	APPROVED APR 01, 1988
METOCLOPRAMIDE HYDROCHLORIDE INTENSOL CONCENTRATE; ORAL	10MG/ML	88 P-0164/CP	ROXANE LABS	NEW STRENGTH	APPROVED JUN 28, 1988
NIFEDIPINE CAPSULE; ORAL	10MG	88 P-0072/ CP0002	MARTEC PHARMS	NEW DOSAGE FORM	APPROVED MAY 11, 1988
NIFEDIPINE CAPSULE; ORAL	20MG	88 P-0072/CP	MARTEC PHARMS	NEW DOSAGE FORM	APPROVED MAY 11, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
PHENYTOIN SODIUM INJECTABLE; INJECTION	100MG/VIAL	87 P-0367/CP	LYPHOMED	NEW DOSAGE FORM	APPROVED FEB 16, 1988
PHENYTOIN SODIUM INJECTABLE; INJECTION	250MG/VIAL	87 P-0367/CP	LYPHOMED	NEW DOSAGE FORM	APPROVED FEB 16, 1988
THEOPHYLLINE CAPSULE, CONTROLLED RELEASE; ORAL	450MG	88 P-0119/CP	RIKER LABS	NEW STRENGTH	APPROVED MAY 11, 1988
THIOTEPA (WITH DILUENT) INJECTABLE; INJECTION	15MG/VIAL	87 P-0382/CP	LYPHOMED	NEW DOSAGE FORM	APPROVED MAY 12, 1988
VERAPAMIL HYDROCHLORIDE CAPSULE, CONTROLLED RELEASE; ORAL	120MG 240MG	87 P-0233/CP	SEARLE	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 26, 1988

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
BENZOYL METRONIDAZOLE SUSPENSION; ORAL	200MG/5ML	85 P-0258/CP	APKON LABS	NEW ESTER NEW INGREDIENT	DENIED MAR 19, 1986
BROMPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE SYRUP; ORAL	2MG/5ML 2.5MG/5ML 12.5MG/5ML	85 P-0237/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
BROMDIPHENHYDRAMINE HYDROCHLORIDE; HYDROCODONE BITARTRATE SOLUTION; ORAL	12.5MG/5ML 2.5MG/5ML	85 P-0255/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
BROMDIPHENHYDRAMINE HYDROCHLORIDE; HYDROCODONE BITARTRATE SYRUP; ORAL	12.5MG/5ML 2.5MG/5ML	85 P-0255/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	100MG/ML (1ML/VIAL) (2ML/VIAL)	87 P-0283/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	DENIED JAN 21, 1988
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	500MG/ML (1ML/VIAL) (2ML/VIAL) (4ML/VIAL)	87 P-0283/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	DENIED JAN 21, 1988

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, SUSTAINED RELEASE; ORAL	75MG	87 P-0355/CP	PARKE DAVIS	NEW DOSAGE FORM NEW STRENGTH	DENIED MAY 11, 1988
HYDROCODONE BITARTRATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE SYRUP; ORAL	1.66MG/5ML 5MG/5ML 6.25MG/5ML	85 P-0389/CP	UAD LABS	NEW COMBINATION	DENIED MAY 11, 1988
HYDROCODONE BITARTRATE; PROMETHAZINE HYDROCHLORIDE SYRUP; ORAL	2.5MG/5ML 6.25MG/5ML	85 P-0256/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
MAGNESIUM ASCORBATE INJECTABLE; INJECTION	10% 20%	88 P-0200/CP	RIM CONSULTING	NEW INGREDIENT	DENIED JUN 10, 1988
METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE; INJECTION	1MG/ML (50ML/VIAL)	87 P-0090/CP	INTL MEDTN SYS	NEW STRENGTH	DENIED FEB 08, 1988

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE; INJECTION	1MG/ML (75ML/VIAL)	87 P-0090/CP	INTL MEDTN SYS	NEW STRENGTH	DENIED FEB 08, 1988
METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE; INJECTION	1MG/ML (100ML/VIAL)	87 P-0090/CP	INTL MEDTN SYS	NEW STRENGTH	DENIED FEB 08, 1988

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-12 BEDTIME DOSING OF 800MG FOR TREATMENT
D-12 BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13 INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14 BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15 SINGLE DAILY DOSE OF 25MG/37.5MG

NEW INDICATION

I-19 ANTIDOTE FOR ACETAMINOPHEN OVERDOSAGE
I-19 CHOLANGIOPANCREATOGRAPHY
I-72 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-73 FOLLICULAR STIMULATION IN IN VITRO FERTILIZATION
I-74 MANAGEMENT OF CONGESTIVE HEART FAILURE
I-75 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-76 HERNIOGRAPHY
I-77 KNEE ARTHROGRAPHY

EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-26	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-27	METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-28	METHOD FOR IMPROVING MEMORY IN MAMMALS
U-29	METHOD FOR TREATING AMNESIA
U-30	METHOD OF POTENTIATING CODEINE ANALGESIA IN MAMMALS
U-31	USE IN LUNG SCANNING PROCEDURES
U-32	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-33	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-34	TREATMENT OF INFLAMMATION

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

57

APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS	3705233	DEC 05, 1989			
		3644353	FEB 22, 1989		NDF	MAY 04, 1991
18116 002	AMCINONIDE; CYCLOCORT	4158055	JUN 12, 1996	U-34		
18498 001	AMCINONIDE; CYCLOCORT	4158055	JUN 12, 1996	U-34		
18644 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	MAR 26, 2002			
18644 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	MAR 26, 2002			
18644 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	MAR 26, 2002			
17920 002	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
		3950333	APR 13, 1993		D-12	APR 30, 1989
17920 003	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
		3950333	APR 13, 1993		D-12	APR 30, 1989
17920 004	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
		3950333	APR 13, 1993		D-12	APR 30, 1989
17920 005	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
		3950333	APR 13, 1993		D-12	APR 30, 1989
17924 001	CIMETIDINE HYDROCHLORIDE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
		3950333	APR 13, 1993		D-12	APR 30, 1989
>ADD>	19201 001	DICLOFENAC SODIUM; VOLTAREN	3652762	MAR 28, 1989	NCE	JUL 28, 1993
>ADD>	19201 002	DICLOFENAC SODIUM; VOLTAREN	3652762	MAR 28, 1989	NCE	JUL 28, 1993
>ADD>	19201 003	DICLOFENAC SODIUM; VOLTAREN	3652762	MAR 28, 1989	NCE	JUL 28, 1993
	18998 001	ENALAPRIL MALEATE; VASOTEC			I-74	JUN 24, 1991
	18998 002	ENALAPRIL MALEATE; VASOTEC			I-74	JUN 24, 1991
	18998 003	ENALAPRIL MALEATE; VASOTEC			I-74	JUN 24, 1991
>ADD>	18998 005	ENALAPRIL MALEATE; VASOTEC	4374829	FEB 22, 2000	NCE	DEC 24, 1990
>ADD>					I-74	JUN 24, 1991
	19309 001	ENALAPRILAT; VASOTEC	4374829	FEB 22, 2000	NDF	FEB 09, 1991
	18981 002	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32	
	18981 003	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32	
	18981 004	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32	
	18830 003	FLECAINIDE ACETATE; TAMBOCOR	4005209	JAN 25, 1996	NS	JUN 03, 1991
		3900481	AUG 19, 1992		NCE	OCT 31, 1990
					NDF	FEB 03, 1991
19452 001	FLUOCINOLONE ACETONIDE; DERMA-SMOOTH/FS	4683235	JUL 28, 2004	U-30		
18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4647591	MAR 03, 2004	U-28		
		4647591	MAR 03, 2004	U-29		
		4626549	DEC 02, 2003	U-26		
		4626549	DEC 02, 2003	U-27		
		4194009	APR 19, 1994			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

58

APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19404 001	FLURBIPROFEN SODIUM; OCUFEN	3793457	FEB 19, 1993			
19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4647447	MAR 03, 2004		NCE	JUN 02, 1993
18061 001	HYDROCHLOROTHIAZIDE; TIMOLIDE 10-25	3655663	APR 11, 1989		D-2	FEB 03, 1991
19129 003	HYDROCHLOROTHIAZIDE; MAXZIDE-25	4444769	APR 24, 2001		NS	MAY 13, 1991
>ADD>					D-15	MAY 13, 1991
>ADD>	18956 002 IOHEXOL; OMNIPAQUE 240				I-19	JUL 29, 1991
>ADD>					I-60	JUL 29, 1991
>ADD>					I-75	JUL 29, 1991
>ADD>					I-76	JUL 29, 1991
>ADD>					I-77	JUL 29, 1991
18956 003	IOHEXOL; OMNIPAQUE 300	4021481	MAY 03, 1994		I-55	FEB 01, 1988
>ADD>					I-58	FEB 01, 1988
>ADD>					I-66	JUL 29, 1991
>ADD>					I-77	JUL 29, 1991
18956 004	IOHEXOL; OMNIPAQUE 350				I-56	MAY 24, 1991
>ADD>					I-77	JUL 29, 1991
19085 001	IPRATROPIUM BROMIDE; ATROVENT	3681500	AUG 01, 1991		NCE	DEC 29, 1991
19777 001	LISINAPRIL; ZESTRIL	4374829	FEB 22, 2000		NCE	DEC 29, 1992
19777 002	LISINAPRIL; ZESTRIL	4374829	FEB 22, 2000		NCE	DEC 29, 1992
19777 003	LISINAPRIL; ZESTRIL	4374829	FEB 22, 2000		NCE	DEC 29, 1992
19487 001	LOPERAMIDE HYDROCHLORIDE; IMODIUM A-D	3714159	JAN 30, 1990			
11719 009	METHOTREXATE SODIUM; METHOTREXATE				ODE	APR 07, 1995
09048 001	METHOXSALEN; 8-MOP				I-72	MAR 23, 1991
19516 002	MORPHINE SULFATE; MS CONTIN				NDF	MAY 29, 1990
18677 001	NABILONE; CESAMET	4087545	MAY 02, 1997	U-7		
19599 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 1998		NCE	MAR 01, 1993
19508 001	NIZATIDINE; AXID	4382090	MAY 03, 2000	U-33		
		4375547	MAR 01, 2000		NCE	APR 12, 1993
19508 002	NIZATIDINE; AXID	4382090	MAY 03, 2000	U-33		
		4375547	MAR 01, 2000		NCE	APR 12, 1993
19009 001	PIRBUTEROL ACETATE; EXIREL	4175128	NOV 20, 1996			
		3786160	JAN 15, 1993			
		3700681	OCT 24, 1989		NCE	DEC 30, 1991
>ADD>	17535 002 PROBUCOL; LORELCO	3862332	JAN 21, 1992			
17881 001	TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT; TECHNETIUM TC 99M	3872226	MAR 18, 1992			
		3863004	JAN 28, 1992	U-31		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

59

APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 1998	U-5	NCE	AUG 07, 1992
		4112097	SEP 05, 1995	U-5		
		4026894	MAY 31, 1994			
19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 1998	U-5	NCE	AUG 07, 1992
		4112097	SEP 05, 1995	U-5		
		4026894	MAY 31, 1994			
19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 1998	U-5	NCE	AUG 07, 1992
		4112097	SEP 05, 1995	U-5		
		4026894	MAY 31, 1994			
19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 1998	U-5	NCE	AUG 07, 1992
		4112097	SEP 05, 1995	U-5		
		4026894	MAY 31, 1994			
19641 001	TERCONAZOLE; TERAZOL 3	4358449	NOV 09, 1999		NCE NDF	DEC 31, 1992 MAY 24, 1991
18207 003	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
		4215104	JUL 29, 1997			
19415 002	UROFOLLITROPIN; METRODIN				I-73	MAR 01, 1991
18817 003	VERAPAMIL HYDROCHLORIDE; CALAN				I-50	DEC 16, 1989
					I-51	DEC 16, 1989
18817 004	VERAPAMIL HYDROCHLORIDE; CALAN				I-50	DEC 16, 1989
					I-51	DEC 16, 1989



SUBSCRIPTION FORM
APPROVED DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
8TH EDITION (1988)

MAIL TO:

DATE:

Superintendent of Documents
Government Printing Office
Washington, DC 20402-9325
(202) 783-3238

PURCHASER:

SHIP TO:
(If different than Purchaser)

CONTACT:

TELEPHONE *(Include Area Code):*

METHOD OF PAYMENT:

- ☐ Charge my GPO Account No. _____
- ☐ Purchase Order No. _____
- ☐ Check/money order enclosed for \$ _____
(Make check or money order payable to Superintendent of Documents)

**AUTHORIZING
SIGNATURE:**

DATE:

DESCRIPTION	QUANTITY	UNIT PRICE	TOTAL PRICE
The 8th Edition is published in March 1988. Subscription includes the Approved Drug Products publication and monthly Cumulative Supplements. DOMESTIC (Stock No. 917-001-00000-6)		@ \$ 79.00	\$
FOREIGN (Stock No. 917-001-00000-6)		@ \$ 98.75	\$
ENTER TOTAL			\$

60

END

O-14-91
